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Gabapentinoids were initially introduced for the treatment of epilepsy, then became 
more widely used in neurology, psychiatry and primary healthcare for the treatment of 
neuropathic pain.  However, gabapentinoids have frequent and debilitating side 
effects, including viral infection, visual disturbance, nystagmus, fever and fatigue, and 
recent evidence suggests that they are increasingly misused.  What is more, recent 
studies have found the number of drug-related deaths in which gabapentinoids are 
implicated is rising.  Detailed and published evidence on the prescribing rates and 
trends of gabapentin and pregabalin is limited. Identifying the prescribing rates and 
trends of gabapentinoids will help us to quantify the scale of the issue and allow us to 
examine whether there are associations with demographic factors and subsequent health 
outcomes.   
Objective  
This research work consists of two projects.  (Part 1) The systematic review, aims to 
summarise the current published evidence on the trends and rates of gabapentin and 
pregabalin prescribing among the general population.  (Part 2) The data-linkage 
analysis, aims to summarise the gabapentin and pregabalin prescribing patterns in 
Tayside over 11 years (2006 to 2016) and Fife over seven years (2010 to 2016).  As 
well as the association of prescribing patterns with sociodemographic factors, the use 
of related health services was also examined by using routinely available linked data 
for 2015 and 2016. 
Methods  
(Part 1) Current published evidence was collected by the following steps: constructing 
a search strategy for searching selected key databases; selecting papers based on the 
selection criteria, data abstraction and quality assessment; preparing a table summary 
for the included papers; and summarizing the included citations.   
(Part 2) A large dataset including 1,091,199 prescriptions and data-linkage from data 
prepared by Health Informatics Centre (HIC) services was analysed.  The prescribing 
patterns of gabapentinoids in Tayside over 11 years (2006 to 2016) and Fife for seven 
years (2010 to 2016) were summarised and compared with Scottish national data using 
Excel and SPSS.  The 36,800 patients who were prescribed at least one gabapentin or 
pregabalin in Tayside and Fife during 2015 and 2016 were linked with the demographic 
file, SMR06 cancer register file, SMR01 hospital admission file, GRO death data, 
accident and emergency data and SMR00 outpatient file, using routine data obtained 
from HIC at the University of Dundee.  The association of prescribing patterns with 
socio-demographic factors was examined using both logistic regression modelling and 
Poisson modelling; while their association with using the health services was 
investigated by a correlation graph.  The age standardised mortality and the 
underlying cause of death were also calculated and summarised. 
Results 
(Part 1) 529 non-duplications were retrieved and 17 citations were included following 
the process of paper selection.  The trends of gabapentin and pregabalin prescribing 




and pregabalin prescribing varied in different countries within the same year.  Among 
the 17 papers, there were five papers of high quality, nine papers of medium quality 
and three papers of low quality.  
(Part 2) The number of gabapentin prescriptions in Scotland rose 4-fold from 164,630 
in 2006 to 694,293 in 2016.  In Tayside these figures were 16,481 in 2006 to 57,472 
in 2016 (x3.5).  In Fife, there were 20,465 prescriptions issued in 2010, rising to 
65,241 in 2016 (x3.2).  Similar rises in the number of pregabalin prescriptions were 
charted in Scotland (x16.1), Tayside (x21.4) and Fife (x2.4). Health board, age and The 
Scottish Index of Multiple Deprivation (SIMD) were significantly related to rates of 
gabapentin and pregabalin prescribing.  The age standardised death rate among the 
population prescribed gabapentinoids was significantly higher than that reported among 
the Scottish general population (p<0.001). 
Conclusion 
(Part 1) The systematic review found that trends of gabapentin and pregabalin 
prescribing varied in different countries.  Because of the limitations of these papers, a 
further and more comprehensive epidemiological study is needed to identify the trends 
of gabapentin and pregabalin prescribing in a general population. 
(Part 2) The overall trends were for gabapentin and pregabalin prescribing rates to rise 
in Tayside and Scotland from 2006 to 2016 and in Fife from 2010 to 2016.  Age, 
SIMD, health board and some levels of rurality were associated with gabapentin and 
pregabalin prescribing rates.  Associated mortality was higher than that in the Scottish 
general population which implied an association between gabapentinoids use and death 
rate.  Further research to investigate the reasons for these findings is needed. 






1. Thesis objectives 
This study aims to investigate the extent of gabapentin and pregabalin prescribing, and 
their associations with socio-demographic factors and subsequent health outcomes.  
To achieve these objectives, this study consists of two projects that are related to each 
other.  The first stage is to conduct a systematic review to identify published evidence 
of gabapentinoids prescribing rates and trends, which we hope will help to quantify the 
scale of the issue.  The second stage is to undertake data-linkage from data prepared 
by the Health Informatics Centre (HIC) at the University of Dundee and analyse this 
dataset to summarise the prescribing patterns of gabapentinoids in Tayside over 11 
years (2006 to 2016) and Fife for 7 years (2010 to 2016).  The association with socio-
demographic factors and use of related health services will also be examined, covering 





2. Systematic review: the prescribing rates and trends of 
gabapentin and pregabalin in the general population 
2.1. Introduction  
Gabapentinoids is a class of drug, which includes pregabalin and gabapentin (1).  
Gabapentin was first approved to treat epilepsy by The Food and Drug Administration 
(FDA) in the USA in 1993, and marketed in 1994 with the trade name Neurontin (2).  
Pregabalin was approved in Europe in 2004 with the trade name Lyrica (2,3).  
Gabapentinoids were initially introduced as a treatment for epilepsy, and now are more 
widely used in neurology, psychiatry and primary healthcare (4–6).  Gabapentinoids 
are approved as the treatment for postherpetic neuralgia, neuropathic pain associated 
with diabetic neuropathy, fibromyalgia, and restless legs syndrome by the Food and 
Drug Administration (FDA) (4,7).  However, in Europe, pregabalin is approved as a 
treatment for neuropathic pain, and as an adjunctive therapy for treatment of resistant 
partial epilepsy and generalized anxiety disorder, but it is not approved to treat 
fibromyalgia (8).  In Canada, pregabalin was introduced in the early 2000s and was 
an antiepileptic drug (AED) with a Health Canada-approved indication for a condition 
other than epilepsy together with carbamazepine, valproic and topiramate, while 
gabapentin was only approved as a treatment for epilepsy (9).  Recently, the off-label 
use of gabapentinoids has increased, including treatment for panic disorder, migraine 
prophylaxis, social phobia, mania, bipolar disorder, and alcohol withdrawal (10). 
Gabapentinoids are used primarily in the treatment of chronic neuropathic pain.  In 
Scotland, gabapentin is one of the first-line recommendations for neuropathic pain and 
pregabalin is in the second-line recommendations (11).  Chronic pain is defined by 
The International Association for the Study of Pain (IASP) as, “pain without apparent 
biological value that has persisted beyond the normal tissue healing time (usually taken 
to be 3 months)” (12).  The IASP defines neuropathic pain as “pain caused by a lesion 
or disease affecting the somatosensory system” (13).  It may be caused by nerve 
damage (for example at surgery) or disease (for example after herpes zoster or in 
diabetes).  A systematic review found estimated prevalence of neuropathic pain in the 
general population to be between 8% and 10% (14). 
Gabapentinoids cross the blood–brain barrier and enter the central nervous system, 




(VDCCs) of neurons as inhibitors (9).  This modifies the release of nerotransmitters 
release and decreases the excitability of nerve cells, resulting in analgesic effects in 
neuropathic pain (16).  Generally, the recommended daily dosing of gabapentin and 
pregabalin for a typical adult are 1200mg-3600mg with three divided doses and 300mg-
600mg with two divided doses respectively (17). 
However, some problems with the use of gabapentinoids also appear.  Firstly, 
gabapentinoids have some common side effects, such as dizziness, sedation, viral 
infection, visual disturbance, nystagmus, fever, drowsiness and fatigue (11,12).  
Secondly, the rising trend of misuse of gabapentinoids has become a concern in public 
health (20,21).  Within Tayside Health Board, Scotland, the number of patients 
prescribed gabapentin and the number of prescriptions dispensed increased from 1993 
to 2011, especially after gabapentin was approved for postherpetic neuralgia in 2002 
(22).  Thirdly, gabapentin and pregabalin can interact with some other substances, 
such as magnesium oxide, phenytoin, morphine, mefloquine, losartan, ethacrynic acid 
and caffeine, which probably cause a higher risk of side effects for patients or may 
reduce the therapeutic effect of each other (22,23).  These concerns may result in a 
recommendation that the prescribing of gabapentinoids should be subject to greater 
control (24,25).   
A study with prescribing data from Tayside, Scotland presented a significantly 
increasing trend of gabapentin prescribing from 2002 (22), but this study did not report 
the prescribing trend of pregabalin.  A report from Public Health England, using the 
primary care prescribing medicine e-dataset, showed that the number of prescriptions 
for gabapentin and pregabalin were 4.9 million and 3.3 million in 2013, which means 
a 46% increase in the number of gabapentin prescriptions and a 53% increase for 
pregabalin respectively compared with 2011 (2.8 million for gabapentin prescriptions 
and 2.16 million for pregabalin), with the statistics of gabapentinoids prescribing 
varying across NHS England regions (Appendix 1) (25).  The average annual increase 
in the number of prescriptions of gabapentinoids was approximately 24%, from around 
1 million in 2004 to 10.5 million in 2015 in England and Wales (26).  According to 
the NHS England annual prescribing cost analysis report, the number of gabapentin 
prescription items increased from 1,260,800 in 2006 to 6,466,482 in 2016 and the 
number of pregabalin prescription items increased by 11.6 times from 476,100 in 2006 




In the United States, the number of gabapentin prescriptions rose from 39 million in 
2012 to 64 million in 2016 when gabapentin was ranked the 10th most commonly 
prescribed medicine (20).  One study, reporting antiepileptic use for epilepsy and 
nonepilepsy disorders from 1998 to 2013 by using administrative health databases in 
Manitoba, Canada, found that gabapentin use increased 55-fold among nonepilepsy 
users from 0.2 per 1000 in the first quarter of 1998/1999 to 11.1 per 1000 in the last 
quarter of 2012/2013 (9).  
An increasing gabapentinoids prescribing trend implicates a rise in the associated 
prescribing costs.  In Scotland, the cost of pregabalin increased from ₤30.41 million 
in 2015 to ₤35.35 million in 2016, while the cost of gabapentin decreased from ₤6.92 
million in 2015 to ₤5.58 million in 2016 (29).  The investigation found that the most 
common reason for gabapentin and pregabalin prescribing was for epilepsy in Scotland 
(29).  In England, the costs of gabapentin decreased from 38.1 million in 2011 to 26.7 
million in 2013, while the costs of pregabalin increased from ₤150.7 million in 2011 to 
₤211.2 million in 2013 (25).  In the United States, pregabalin became the 8th drug 
listed in invoice drug spending in 2016, with costs of $4.4 billion which was almost 
twice the pregabalin cost in 2012 (20).   
However, the gabapentinoids prescribing trends in the UK or United States cannot be 
mirrored in all other countries; as detailed and published evidence on the prescribing 
rates and trends of gabapentin and pregabalin in other countries is quite limited, the 
worldwide prescribing trend or rate of gabapentinoids prescribing in recent years 
remains unknown.  Thus, with the consideration of patient safety, there is a need to 
summarise the gabapentin and pregabalin prescribing rates and trends in the general 
population, thereby resulting in a more comprehensive and stronger evidence base 
which will inform local and national strategies to rationalize the prescribing and safety 
of gabapentin and pregabalin in Scotland.  Thus, this systematic review aims to 
summarise current published papers in relation to the prescribing rates and trends of 
gabapentin and pregabalin for the general population. 
2.2. Methods 
2.2.1. Search strategy 
2.2.1.1. Pre-search 




Collaboration (CDSR) which contains systematic reviews produced by Cochrane 
Collaboration and PubMed was searched to gauge the existing evidence of 
gabapentinoids prescribing rates and trends. 
After the pre-search, a structured search strategy was developed to find published and 
peer-reviewed articles reporting prescribing rates and trends of gabapentinoids. 
2.2.1.2. Literature search 
Considering the characteristics and accessibility of databases, the key electronic 
databases searched were MEDLINE Ovid, Embase Ovid, Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), PsycINFO, CDRS, and the Centre of Reviews 
and Dissemination (CDR).  The CDR database contains meta-analysis and systematic 
reviews in medicine, including the National Health Service Economic Evaluation 
Database (NHS EED), Health Technology Assessment (HTA) and the Database of 
Abstracts of Reviews of Effects (DARE). 
The search commenced December 2017 and alerts of my search for each database were 
set and checked for newly published results periodically until the end of 2018.  Any 
new information of the updated results would be listed in the article if the newly 
published articles met the inclusion criteria of this review. 
With study terms to include drug names, prescription trends and statistics decided, the 
systematic review team were Yiling Zhou (YZ), Jennifer Watson (JW) and Blair Smith 
(BS).  The drug names; gabapentin and pregabalin, their most commonly known trade 
names (Neurontin and Lyrica, respectively), and their classification (gabapentinoids) 
were used in the search.  For prescription, I searched using keywords, script or scripts, 
drug utili?ation, drug use, drug consumption and prescri*, along with their Medical 
Subject Headings (MeSH terms).  MeSH terms included: gabapentin; pregabalin; 
prescription; prevalence; incidence; drug utilisation.  To specify statistics, I used the 
following search terms; trend, rate, pattern, prevalence, incidence, number, quantity, 
amount, count and sum.  According to the inclusion and exclusion criteria set, the year 
of publication was limited to 1993-current (as gabapentin was introduced in 1993); 
English or Chinese language were searched, and any paper that mentioned adults was 
included.  The search strategy was concordant in each database with only tiny 
adjustments due to the unique feature of each database. 




which were based on the Population, Intervention, Comparators, Outcomes and Study 
designs (PICOS) principle.  However, in this study, comparator which is more 
appropriate in the selection criteria for clinical trial studies, was not used because this 





2.2.1.3. Research question: What are the trends of gabapentinoids prescribing rates in 
the general adult population?  
2.2.1.4. Inclusion criteria 
Population     
 The general population, including all people with free age range. 
Intervention    
 gabapentinoids 
 gabapentin 
 pregabalin  
Outcome     
 The prescribing rate (per specified time period)  
 The prescribing trend (over several time periods) 
Study design    
 Observational study with large dataset: survey, cohort study, cross-sectional study, 
case control study 
 Systematic review 
 Meta-analysis 
 Review 
Language     
 English and Chinese 
Time period    
 1993 to current 






2.2.1.5. Exclusion criteria 
Population  
 Only including children (under 18) 
 Animal 
 Prison population 
 Post-mortem study 
Outcome   
 Articles only showing the misuse rate of gabapentinoids 
Study design  
 Case studies 
Language  
 Others except for English and Chinese 
Time period 
 Before 1993 
 Articles unobtainable after review period 
Article design  
 Grey literature 
 Non-peer reviewed 
 
The general population data were of interest, so animal studies and papers using only 
populations aged under 18 were excluded.  Papers focusing on prison populations and 
post-mortem would be excluded, because they are too specific to be representative of 
the general population; for example, a prison population is more likely to have 
substance abuse and gabapentinoids prescribing (30).  However, the study population 
with specific age group but not only children, specific disease or exposure to specific 
medicine would be acceptable if they report the trends of gabapentinoids, because they 
are quite relevant to this systematic review except for the study population and they can 
provide the trends of gabapentinoids among different age groups or disease.  All 
observational studies would be accepted except case studies, because case studies may 
only include several cases, from which we cannot generate a prescribing rate or reflect 
the prescribing pattern of the general population.  Due to our resource limitation, we 
read English and Chinese languages, thus, papers published in other languages were 




gabapentin was introduced in 1993.  As depicted in the inclusion criteria, only peer-
reviewed papers were included. 
2.2.2. Paper selection 
After searching each database separately, I combined all the results and imported them 
into Mendeley, a references-managing software.  The duplications were firstly 
excluded by Mendeley automatically, and then were checked manually.  YZ, JW and 
BS made up the review team.  After pre-selection of a few papers following the 
literature searching, we discussed how to apply the inclusion and exclusion criteria to 
the papers.  Firstly, JW and I scanned the titles independently.  The citation would be 
excluded only when excluded by both reviewers; the remainder of citations would go 
to the next screening step, abstract screening.  YZ and JW scanned the abstracts 
independently.  The citation would be excluded if it was excluded by both reviewers.  
Editorials without new data only commenting on other studies were excluded.  
Following the abstract screening, the full text of the included papers was checked by 
the two reviewers (YZ, JW,) independently.  The reference lists of included papers 
were checked to ensure any related papers had not been missed.  During the selection 
process steps, if the two reviewers could not reach an agreement, a final decision on 
inclusion/exclusion was reached in discussion with the third reviewer, BS.  The 
selection process steps which were followed are detailed on a flow chart based on the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow 
chart (Appendix 2). 
2.2.3. Data abstraction 
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
checklist (Appendix 3) is a structured, standardized checklist, commonly used to assess 
the quality of observational studies and gives the guidelines for what should be included 
in an observational study.  The data abstraction form in this study was designed based 
on the STROBE checklist, as most of the included studies are observational studies.  
The data abstraction form did not include all things presented by the STROBE checklist.  
The data abstraction form (Appendix 4) included title, abstract, introduction, methods 
(including study design, setting location, study period, data source, study population, 




prescribing rate, prescribing trend), main findings, limitations related to prescribing 
trend or rate of gabapentinoids.  
2.2.4. Quality assessment 
Quality assessment tools are used to ensure the results of the systematic review capture 
and summarise the quality of evidence.  All included papers were observational 
studies, and the quality assessment tool in this systematic review was designed based 
on two existing quality assessment tools: the National Heart, Lung and Blood Institute 
(NHLBI) (Appendix 5) which is a quality assessment tool widely used for Cohort and 
Cross-sectional studies; and the quality criteria for critical appraisal of observational 
studies which was adapted from the CRD handbook (Appendix 6). 
2.2.5. Data summary 
The final selected papers were summarised in tables according to the study type.  The 
tables were designed based on the characteristics of the study design type: cross-
sectional studies, cross-sectional time series studies and cohort studies.  Due to there 
being too much information from cross-sectional study to summarise, two kinds of 
tables were designed to summarise the information: one was to summarise the 
demographic information, and the other was to summarise the definition of interest 
outcome, prevalence and main findings.  For cohort studies and cross-sectional time 
series studies, one table was designed for each type of study, including demographic 
information, definition of interest outcome, prevalence and main findings.  The 
demographic information contained the basic information about the study (author, 
country, published year, study period), study population (size, clinical status, age, 
exposure, cohorts), data source and exposure (gabapentin, pregabalin or both).  Main 
findings mainly included the prescribing trends and associated demographic factors.  
Limitations were also summarised for each study, but they would be discussed in the 
Discussion section, not listed in the summary table. 
2.3. Results 
2.3.1. Characteristics of studies 
We identified 529 articles from the key medical databases after excluding duplication 
(Figure 1).  These articles were then either included or excluded after being reviewed 




After reviewing the abstracts, there were 71 papers identified for full text review.  Of 
these 12 papers proved to be conference abstracts and were thus excluded, according to 
the review protocol.  Therefore, we had 59 papers with full text for review.  Six 
articles were selected for full text review from manually checking the reference lists of 
the 59 papers for full text review.  Any papers which only reported on a study 
population aged under 18, only focusing on a specific population, such as patients 
during status epilepticus period, failure to mention gabapentinoids prescribing, or 
focusing on the treatment and lacking comparable trends in different periods were 
excluded at the step of full text screening (Figure 1). 
The manual reference checking step found three potential papers (from the six papers 
included in the first reference checking).  However, two papers only studied the 
population aged under 18, and one paper only investigated the gabapentin prescribing 
proportion, lacking the prescribing trend.  Thus, these three papers were excluded. 
Finally, 17 papers were selected for data abstraction and quality assessment.  Among 
the 17 papers, there were 13 cross-sectional studies (8,31,40–42,32–39), two cross-
sectional time series studies (43,44), and two cohort studies (45,46).  Among these 17 
papers, ten papers were published after 2013 and the earliest one was published in 2007.  
All 17 papers were written in English and we did not find any Chinese articles when 
we searched the selected databases using the search strategy.   
The size of study population among the 17 papers varied from 2,163 (42) to 4,985,870 
(38).  The age ranges of study populations were also different; such as all age range, 
aged 15 or over, all adults, aged 20 or over, aged 60 or over and aged 65 or over.  For 
the country setting, both of the cross-sectional time series studies were from Canada 
(43,44); and the two cohort studies, were from USA (45) and the UK (46).  Among 
the cross-sectional studies, there were five papers from Italy (31,32,34,36,42), three 
papers from Norway (35,38,41), and one paper each from Scotland (33), Sweden (8), 
Taiwan (China) (39), Australia (37) and New Zealand (40).  The study period of the 











Replications were deleted 








71 articles were 
included after 
abstract screening 
17 articles were 
included 
59 articles with full 
text were retrieved 





42 papers were excluded 
 Lack of comparable prescribing rates between different 
periods：26 
 Focus on the pattern of number of prescriptions per person 
in one period：1 
 Specific population：3 
 Co-prescription with other drugs：2 
 Only focus on treatment, without numeric prescribing 
information：6 
 No gabapentin or pregabalin prescribing：4 
Reference list 
checking 
Figure 1. Flow chart of study selection 
135 articles were excluded 
 Abstract did not report 
prescribing, numeric data, 
gabapentinoids or any related 
gabaeptninoids   
323 papers were excluded 
 Title did not include 
gabapentinoids or any disease or 
medication related to 
gabapentinoids 
12 papers were excluded 









2.3.2. Cross-sectional studies 
Table 1-a summarises the demographic information and Table 1-b summarises the 
definition, prevalence and main findings from the 13 cross-sectional papers.  Among 
the 13 papers, there were nine papers studying both pregabalin and gabapentin (31–
38,42), three papers only mentioning gabapentin (39–41) and one paper focusing on 
pregabalin (8).  The majority of the 13 papers used the general population with 
different age ranges, while the paper written by Alessandro et al (34) studied patients 
prescribed at least one AED and who were aged 65 or over.  The paper written by 
Prasad et al (40) studied patients who were aged 65 or over whereas for the paper 
written by Galimberti et al (42), the study population were the residents in 21 nursing 
homes.  Additionally, the definition of exposures used by these papers was different.  
For example, some papers used the exposure, commencing gabapentin or pregabalin 
prescription during the study period (31–33,45,46), while others used exposure as 
prescribed at least one gabapentin or pregabalin during the study period.  The 
differences of the study population and exposure choice make the results difficult to 
synthesize.    
The definitions of the outcome of interest were dissimilar, mainly dependent on how 
the data were collected.  To quantify the gabapentin or pregabalin prescribing, there 
were seven papers using the WHO defined daily dose (DDD) (31,34,35,37,38,40,41). 
(The DDD is the assumed average maintenance dose per day for a drug used for its 
main indication in adults).  Two papers used the proportion of number of patients who 
were prescribed gabapentin or pregabalin (8,33), two papers used the number of 
patients prescribed gabapentin or pregabalin (39,42), three papers used prescribing 
incidence (31,32,34) and two papers used prevalence rates (34,36,39).  Some papers 
reported more than one outcome to quantify the gabapentin or pregabalin prescribing 
(31,34,39). 
One paper from Taiwan, China (39) aimed to evaluate the prevalence of prescription 
and use of antiepileptic drugs (AEDs) for the treatment of epilepsy in a nationwide 
population, which included gabapentin and pregabalin.  Thus, in this study, it included 
the prevalence of gabapentin prescription in a nationwide population in Taiwan from 
2003 to 2007 and it also compared the prevalence among patients with epilepsy, pain 




year increased from 2003 (256) to 2007 (820).  This study also found that the 
proportion of gabapentin prescriptions increased slightly from 2003 to 2006 and then 
decreased slightly in 2007 among patients with epilepsy (2.5% - 3%) and psychiatry (2% 
- 4%), while the proportion among patients with pain disorder increased significantly 
from 8% (2003) to 28% (2007).  Another finding was that older patients aged 55 and 
over were the age group that was prescribed gabapentin most often (around 47.7% to 
68.6 %) amongst patients receiving gabapentin each year.  
One study from Norway conducted by Landmark et al (41) aimed to investigate how 
AEDs were used at the National Centre for Epilepsy in Norway, providing a graphical 
presentation about the trends of gabapentin use in Norway from 1996 to 2005.  The 
number of DDDs of gabapentin in Norway increased gradually from <0.1 per 1,000 
persons per day in 1996 to around 1.2 in 2004 and then slightly decreased to 1.1 in 2005.  
Another study conducted in Norway (38) found the number of DDDs per 1,000 persons 
per day of pregabalin increased slightly from 2008 (2.07) to 2012 (2.23), and the 
number of DDDs of gabapentin increased from 0.75 in 2008 to 1.9 in 2012.  Another 
study undertaken in Norway (35) calculated the number of DDDs per 1,000 persons per 
day of gabapentin and pregabalin among patients with neuropathic pain, epilepsy and 
psychiatric illness respectively using the data from the Norwegian prescription database 
and statistics Norway during 2004 to 2015.  It was found that, amongst patients with 
psychiatric illness, the number of DDDs of pregabalin increased from less than 0.01 in 
2008 to 0.18 in 2015 per 1,000 persons per day and for patients with epilepsy, the 
number of DDDs of pregabalin increased from 0.01 per 1,000 persons per day in 2005 
to 0.5 in 2012.  Among patients with neuropathic pain, the number of DDDs per 1,000 
patients per day of gabapentin in 2015 (4.8) was over 11 times that in 2004 (0.35).  
However, this study only studied patients who were aged 60 or over. 
One study from Sweden (8) aimed to assess prescribing patterns, sociodemographic 
characteristics and previous disease history in patients receiving pregabalin.  The 
study used the proportion of patients who were prescribed pregabalin at least once to 
present the pregabalin prescribing rate.  It was found that the prescribing rate 
increased for both women and men, and that the increase for women (2.2% in 2006 to 
7% in 2009) was greater than that for men (1.5% in 2006 to 4.2% in 2009).  This study 




One paper from Italy (32) aimed to analyse the prescribing patterns of both newer and 
older AEDs.  This study selected all people aged over 15 in Caserta and used yearly 
incidence figures to describe the gabapentin or pregabalin prescribing rate each year.  
This study found that, compared with the incidences in 2005 (50.7 per 1,000 persons 
for gabapentin and 29.2 per 1,000 persons for pregabalin), the incidence of gabapentin 
decreased dramatically in 2011 (9.3 per 1,000 persons), while the incidence of 
pregabalin increased significantly in 2011 (42.2 per 1,000 persons).  Another study 
from Italy (36) aimed to evaluate the prevalence of prescribing patterns of AEDs in 
Italian general practice.  A one-year prevalence rate was used to describe gabapentin 
and pregabalin prescribing.  It was found that the prevalence of gabapentin use 
increased gradually from 0.4 per 1,000 persons in 2000 to 8 per 1,000 persons in 2004 
and then slightly decreased to 7.5 per 1,000 persons in 2005.  The same study found 
the prevalence of pregabalin prescribing in 2005 was 2.5 per 1,000 persons, as 
pregabalin was only generally marketed from 2004 in Italy.  Another paper in Italy 
(34) found the incidence of gabapentin decreased from 12.5% in 2004 to 2.6% in 2007, 
while the incidence of pregabalin increased from 5.5% in 2005 to 6.7% in 2007.  The 
prevalence of pregabalin prescribing fluctuated from 2005 to 2007 (7.3% in 2005, 25.2% 
in 2006, 13.1% in 2007).  The number of DDDs of gabapentin prescribed per 1,000 
persons decreased from 1.66 in 2005 to 0.94 in 2007, while for pregabalin, it fluctuated 
during 2005 to 2007, 0.25 in 2005, 1.51 in 2006 and 1.03 in 2007.  However, this study 
only included patients who received at least one AED and were aged 65 or over.  
Another Italian study (31) found the incidence of gabapentin prescribing decreased 
from 5.53% in 2004 to 4.73% in 2005, and the number DDDs of gabapentin prescribed 
per 1,000 persons per day fluctuated: 0.6 in 2003, 0.55 in 2004 and 0.59 in 2005.  The 
final study in Italy (42) found 68 patients were prescribed gabapentin and 19 patients 
were prescribed pregabalin in 2012 compared with no patients being prescribed 
gabapentin or pregabalin in 2000, but this study only included 2,163 patients resident 
in a nursing home. 
The paper from Australia (37) studied all patients entered in the Medicare Australia and 
Drug Utilisation Sub-Committee database and found the number of prescribed DDDs 
of gabapentin increased slightly from 2003 to 2007 (0.43 to 0.49 per 1,000 persons per 
day).  The trend with pregabalin also increased from 2005 to 2007 (0.03 to 0.18 per 




prescribed DDDs of gabapentin increased dramatically from 0.35 in 2005 to 1.37 in 
2006 and rose steadily to 1.58 in 2008 and then decreased gradually to 0.05 in 2010, 
then declined slightly to 0.04 in 2013 (per 1,000 persons per day) among all people 
aged over 65.  The paper from Scotland found the proportion of patients who were 
prescribed gabapentin and pregabalin was much greater in 2010 ( 1.2 % for gabapentin 
and 0.26% for pregabalin) than that in 1995 ( 0.02 % for gabapentin and less than 0.1% 




Table 1-a. Summary of gabapentinoid prescribing trends or rates in cross-sectional studies-demographic information 
Study Study population Exposure Data source 




883,323 in 2004,  
1,013,855 in 2010, 
1,121,796 in 2015. 




database and statistics 
Norway 




20,370 in 2005,  
25,932 in 2013. 
All people aged 65 and over. 
Gabapentin New Zealand Ministry of 
Health 




4,737,200 in 2008,  
4,799,252 in 2009,  
4,858,199 in 2010,  
4,920,305 in 2011,  
4,985,870 in 2012 









168,397 inhabitants aged >=15 









Around 2 million inhabitants in 
Stockholm 
Pregabalin  Swedish prescribed drug 
register, National patient 
register, the cause of death 
register, the regional 
primary care database of 
Stockholm County Council, 
Statistics Sweden 
Ruscitto et al (33) 
2014 
Scotland 
1995 and 2010, two years 
301,020 in 1995 
311,881 in 2010 




Health informatics centre 
database 




About 600,000 in the random 
sample of NHIRD cohort. 
All people, and people aged 18 or 
over were also selected out. 
Gabapentin The national health 
insurance research database 








Medicare Australia and 
Drug Utilisation Sub-
Committee database 




127,389 patients registered in 93 
GPs in the Arianna database 
during 2003-2005  








17,071 elder people, 1,609 
received at least one AED. 





unit Arianna databases 





All individuals registered in the 
320 GPs` lists. 




Health search database 





The whole population in Norway 
Gabapentin N/A 
Galimberti et al (42) 
2015 
Italy 
2000 and 2012, two years 
2,163 residents in 21 nursing 
home  
Aged 60 or over 
Gabapentin and 
pregabalin 
Collected by the study 








Table 1-b. Summary of gabapentinoid prescribing trends or rates in cross-sectional studies-main findings 
Study Definition Prevalence Main findings 




DDDs= sum of DDDs subgroup 
(epilepsy, neuropathic pain or 
psychiatry disorder) 
*1000/365*number of 
inhabitants aged 60 or over in 
Norway 
(per 1000 persons per day) 
Epilepsy: 
Pregabalin: 0.01 in 2005, over 0.5 
in 2012,  
below 0.5 in 2013,  
slightly above 0.5 in 2015    
Gabapentin:  1.3 in 2004, 0.15 in 
2012, 0.25 in 2013, 0.21 in 2015.  
Neuropathic pain: 
Pregabalin: (0.01) 2004, 
2009 (3.1), 2010 (2.8),  
2015 (4.3). 
Gabapentin: (0.35)2004, 2015 (4.8). 
Psychiatry: 
Pregabalin: over 0 in 2008, 2012 
(0.18),  
2015 (about 0.18). 
 
Epilepsy: 
Pregabalin: increase from 
2005 to 2012, and decrease 
from 2012 to 2013, then 
increase from 2013 to 
2015. 
Gabapentin: decrease from 
2004 to 2012, and increase 
in 2013, then decrease 
from 2013 to 2015.  
Neuropathic pain: 
Pregabalin: increase from 
2004 to 2009, decrease in 
2010, then increase from 
2010 to 2015.  
Gabapentin: increase from 
2004 to 2015. 
Psychiatry: 
Pregabalin: increase from 
2008 to 2012, and decrease 
in 2013, then increase from 
2013 to 2015. 





The WHO defined daily dose 
(DDD) method was used to 
describe the number of older 
people on a defined standard 
daily dose per thousand older 
people (>=65 years) per day 
(TOPD) 
(per 1000 persons per day) 
0.35 in 2005,  
1.37 in 2006, 
1.52 in 2007,  
1.58 in 2008,  
1.00 in 2009,  
0.05 in 2010,  
0.05 in 2011,  
0.04 in 2012,  
0.04 in 2013. 
2005 to 2008 increase, 
2008 to 2013 decrease 




The utilisation of AEDs is 
presented as DDDs/1000 
inhabitants/day 
Pregabalin: 
2.07 in 2008,  
2.1 in 2009,  
2.11 in 2010, 
2.21 in 2011,  
2.23 in 2012 
Gabapentin: 
0.75 in 2008,  
1.25 in 2009,  
1.65 in 2010,  
1.8 in 2011,  
1.9 in 2012. 
The DDDs of pregabalin 
increased from 2008 to 
2012. 
The DDDs of gabapentin 
increased from 2008 to 
2012. 





Yearly incidence = the number 
of new users /the number of 
inhabitants alive and registered 
in the GPs` lists and who were 
free from any AED prescription 
in the previous year. 
New user was defined as a 
patient receiving a first AED 
during the observation period, 
without any recorded AED 
prescription in the previous 365 
days. (per 1000 inhabitants) 
Gabapentin: 
50.7 in 2005,  
9.3 in 2011. 
Pregabalin: 
29.2 in 2005,  
42.2 in 2011. 
 
Incidence of gabapentin 
decreased dramatically in 
2011 compared with 2005 
Incidence of pregabalin 
increased significantly in 






The proportion = number of 
patients in the region dispensed 
at least one prescription of 
pregabalin each year per 1000 
inhabitants between 6/2005 to 
12/2009. (%) 
Women around 2.2, men 1.5(2006) 
Women around 4.5, men 2.8(2007) 
Women around 6.1, men 3.7(2008) 
Women around 7, men 4.2 (2009) 
From 2006 to 2009, the 
prescribing rate for both 
women and men increased 





Table 1-b cont`d. Summary of gabapentinoid prescribing trends or rates in cross-sectional studies-main findings 
Study Definition Prevalence Main findings 




1995 and 2010 
two years 
The portion of patients who 
currently prescribed gabapentin or 
pregabalin. 
Current prescribing defined as 
receiving a dispensed medication 
in the 84 preceding (and 




54 patients (0.02%) in 1995,  
3,682 patients (1.2%) in 2010 
Pregabalin: 
0 in 1995,  
800 patients (0.26%) in 2010 
Gabapentin increase in 
2010 compared with 1995 
Pregabalin increase in 2010 
compared with 1995 




Number of patients who 
prescribed gabapentin. 
Number of patients: 
256 in 2003, 416 in 2004,  
538 in 2005, 674 in 2006,  
820 in 2007 
The total number of 
gabapentin users increase 
from 2003 to 2007.  
Older people are more 
likely to prescribe 
gabapentin (>=55). 
Male people are more 
likely to prescribe 






DDD per 1000 population per 
day. (1000 inhabitants per day) 
Gabapentin: 
0.43 in 2003,  
0.48 in 2005, 
0.49 in 2007. 
Pregabalin: 
0.03 in 2005, 
 0.18 in 2007. 
The amount of gabapentin 
used increased from 2003, 
2005 to 2007, and the 
amount of pregabalin used 
increased between 2005 
and 2007 
 





1. incidence = the number of new 
users/ the number of subjects alive 
and registered in the GPs` lists. 
(per 1000 persons) 
New users are defined as patients 
receiving at least one AED 
prescription in the observation 
year, without any recorded AED 
prescription in the previous one. 
 
2. DDD per 1000inhabitants/day. 
Incidence: 
Pregabalin, 2.18 in 2005 
Gabapentin,  
5.53 in 2004,  







(per 1000 persons per day) 
The incidence of 
gabapentin decreases from 
2004 to 2005. 
The volume of gabapentin 
decreases from 2003 to 
2004 and then increases 
from 2004 to 2005. 




1. One-year prevalence of 
gabapentin (pregabalin) = the ratio 
between the number of patients 
who received >=1 gabapentin 
(pregabalin) and the number of 
subjects alive and registered in the 
GP`s lists, for each year.  
(per 1000inhabitants) 
 
2. Incidence of gabapentin 
(pregabalin) = the number of new 
user / the number of subjects free 
from AED prescription in the 
previous year.  New user= a 
patient receiving at least one 
gabapentin (pregabalin) during 
the observational year, without 
any record 
gabapentin(pregabalin) prescribed 
in the previous one.  (Rates per 
1000inhabitants) 
 
3. DDD per 1000 inhabitants 
per day.   
1. Prevalence: 
pregabalin  
7.3 (6-8.6) in 2005, 25.2(22.8-
27.5) in 2006, 13.1 (11.4-14.8) in 
2007.   
2. Incidence: 
Gabapentin,  
12.5 in 2004 (10.8-14.2), 9.7 in 
2005, 7.6 in 2006, 2.6 (1.8-3.4) in 
2007 
Pregabalin,  
5.5 (4.4-6.6) in 2005, 18.1 (16.1-




1.58 in 2004,  
1.66 in 2005,  
1.35 in 2006,  
0.94 in 2007. 
Pregabalin,  
0.25 in 2005,  
1.51 in 2006,  
1.03 in 2007. 
1. Among newer AED, 
gabapentin was the most 
prescribed drug until 2005. 
Pregabalin, marketed in 
Italy in 2004, overcame 
gabapentin use during 2006 
and 2007. Pregabalin 
prescribing increase from 
2005 to 2006, followed a 
reduction in 2007. 
2. Incidence 
Gabapentin, decrease from 
2004 to 2007 
Pregabalin, increase from 
2005 to 2006 and decrease 
from 2006 to 2007 
3. DDD 
Gabapentin, increase from 
2004 to 2005, decrease 
from 2005 to 2007 
Pregabalin, increase from 
2005 to 2006 significantly, 
decrease from 2006 to 
2007. 





Table 1-b cont`d. Summary of gabapentinoid prescribing trends or rates in cross-sectional studies-main findings 
Study Definition Prevalence Main findings 





1-year prevalence = the number 
of gabapentin or pregabalin users/ 
the number of subjects alive and 
registered in the GP lists per year 
(per 1000 inhabitants) 
Gabapentin: 
0.4 in 2000,  
1.8 in 2001,  
5.1 in 2002,  
7.6 in 2003,  
8.0 in 2004,  
7.5 in 2005. 
Pregabalin: 
2.5 in 2005. 
The prevalence of 
gabapentin using increased 
from 2000 to 2004 and 
then slightly decreased. 





DDD (per 1000 inhabitants) N/A The DDD of Gabapentin 
increased from 1993 to 
2003, and then decreased 
from 2003 to 2004. 






the number of patients who 
prescribed at least one gabapentin 
(pregabalin) 
Gabapentin:  
<0.001 in 2000, 
67.8 in 2012. 
Pregabalin:  
<0.01 in 2000,  
18.9 in 2012. 
The number of patients in 
this study population 
increased in 2012 
compared with that in 2000 




2.3.3. Cross-sectional time series studies 
The two cross-sectional time series studies were summarised in Table 2.  Kwok et al 
(44) studied pregabalin but not gabapentin.  The study aimed to identify the effect of 
change of medicine policy on pregabalin use and the characteristics of new patients 
commencing pregabalin under the expanded access.  The study population was all 
Ontario Drug Benefit (ODB)-eligible individuals.  This study used the proportion of 
patients who were prescribed pregabalin to quantify the rate of pregabalin prescribing 
and compare the trends of pregabalin prescribing between ODB-eligible patients aged 
under 65 and ODB-eligible patients 65 and older.  It was found that the rate of 
pregabalin prescribing in 2014 (19.7) was 22-fold times more than that in 2006 (0.89) 
(per 1,000 ODB-eligible patients), and nearly 30 times more than that in 2013 (0.7) 
among ODB-eligible patients 65 and older.  Among the ODB-eligible patients under 
65, the rate of pregabalin increased gradually from 0.1in 2006 to 1.8 in 2013 and soared 
to 28.6 in 2014 (per 1,000 ODB-eligible patients).  It also found that the rate of 
pregabalin in the younger age group was consistently greater than in the older age group.   
Leong et al (43) studied gabapentin prescribing in Manitoba, Canada and the study 
period was over 15 years (1998-2013).  The objective of this study was to identify the 
trends in AED use in Manitoba.  As gabapentin was also used to treat epilepsy, it was 
included as an AED in this study.  This study compared the prevalence of gabapentin 
prescribing between epileptic patients and non-epileptic patients.  It was found the 
prevalence of gabapentin had a 55-fold increase from 0.2 in the first quarter of 1998 to 
11.1 in the last quarter of 2013 among non-epileptic patients (per 1,000 persons), while 
it was relatively stable among epileptic patients (around 25 per 1,000 persons) and the 
prevalence of gabapentin prescribing among epileptic patients was consistently greater 
than among non-epileptic patients.  The results could reflect the gabapentin use in the 
Manitoba general population from 1998 to 2013.  However, the results were only 
shown graphically as line charts, so this study failed to provide the exact value for the 









study period study population 
(study size, age, 
clinical status) 
exposure data source Definition Prevalence  Main findings 






2006 and 2014. 
All ODB-eligible 
individuals who 
were dispensed a 
pregabalin. 







The rate of pregabalin 
= the number of 
patients who 
prescribed pregabalin 
/ the total ODB 
eligible patients each 
year 
0.1 in 2006, 
1 in 2013,  
22 in 2014. 
(per 1000 ODB 
eligible people) 
Increase from 2006-2014， 
22-fold increase in 2014 compared with 
2013. 
Leong et al (43) 
2016 
Canada 




Gabapentin  Administrative 
health databases 
in Manitoba 
Prevalence every 3 
months in subgroup= 
the number of 
individuals filling a 
prescription for 
gabapentin or 
pregabalin/ the total 
number of individuals 
with (without) 
epilepsy and alive in 
Manitoba at the 
beginning of the given 
interval (per 1000 
individuals) 
0.2 in first quarter 
of 1998/1999,  





(per 1000 persons) 
For individuals without epilepsy, the 
prevalence of gabapentin increased 
dramatically from 1998 to 2013 (55-fold 
increase). 
For individuals with epilepsy, the 
prevalence of gabapentin fluctuated at 
the level, around 25 users per 1000 




2.3.4. Cohort studies 
The two cohort studies are summarised in Table 3.  Of the two papers, one paper (46), 
of which the objectives were related to our study, was to update the incidence rates and 
prescribing practices for neuropathic pain in a UK population, while the other paper 
(45) focused on examining medication adherence and healthcare costs for combination 
prescribing and monotherapy initiators in South Carolina, but it also reported related 
information about pregabalin prescribing.  Marlow et al only studied pregabalin (45), 
while Hall et al studied both pregabalin and gabapentin (46).  The study periods of the 
two papers were both six years, but the selection of study populations was quite 
different.  The study by Hall et al, undertaken in the UK (46), studied the general 
population, while the paper written by Marlow et al in USA (45) reported a specific 
population with only 1,881 patients who were diagnosed with fibromyalgia and 
commenced at least one of the listed drugs, Duloxetine, Milnacipran, Venlafaxine and 
Pregabalin. 
The cohort study written by Hall et al (46) used the number of patients with a first 
gabapentin or pregabalin prescription to quantify the gabapentinoids prescribing.  It 
was found that the number of patients prescribed gabapentin and pregabalin both 
increased from 2005 to 2010 in the study population: for gabapentin (4,210 patients in 
2006 to 7,207 patients in 2010); for pregabalin (2,719 patients in 2006 to 5,416 patients 
in 2010).   
In the paper by Marlow et al (45), even though the main objective was not about 
pregabalin prescribing, they did report some information about pregabalin prescribing.  
This paper found the number of patients commenced on pregabalin fluctuated between 









study period study population (study size, 
age, clinical status) 
Study drug of 
gabapentinoid 
data source Definition Prevalence  Main findings 




2006-2011 1881 People with 
Fibromyalgia Syndrome 








claims data for 
FMS patients in 
South Carolina 
The number of 
patients who initiated 
pregabalin. 
Medication initiation 
was defined as no 
prescription coverage 
for medication in the 
prior 90 days, and the 
index date was 
defined as the 
medication initiation 
date. 
The year is the initiate 
index year. 
2007 (164),  
2008 (304),  
2009 (209),  
2010 (738),  
2011 (612). 
 
Increase from 2007 to 2008, 
decrease from 2008 to 2009, then 
increase from 2009 to 2010, and 
then decrease from 2010 to 2011 
 
Hall et al (46) 
2013 
UK 
2005-2010 All patients who were 
permanently registered at a 
GPRD practice at any time 







The number of 
patients with first 
prescriptions of 
gabapentin or 
pregabalin in each 
year. 
Gabapentin: 
4,210 in 2006, 
5,433 in 2007, 
6,083 in 2008, 
6,938 in 2009, 
7,207 in 2010. 
Pregabalin: 
2,719 in 2006, 
2,979 in 2007, 
3,652 in 2008, 
4,333 in 2009, 
5,416 in 2010. 
The number of patients with first 
prescription of gabapentin 
increased from 2006 to 2010. 
The number of patients with first 
prescription of pregabalin 




2.3.5. Quality assessment 
There were five papers of high quality, nine papers of medium quality and three papers 
of low quality, summarised in Table 4.  The nine papers of medium quality included 
obvious limitations.  Among these nine papers, the study period was a limited number 
of years.  For example, the paper written by Alacqua et al (31) only reported 
gabapentin prescribing rates in 2004 and 2005, and pregabalin prescribing rate in 2005, 
failing to provide the trends over years.  The other one written by Ruscitto et al (33) 
only compared the number of patients who were currently prescribed gabapentin or 
pregabalin between two years, 1995 and 2010, so it was not able to show the annual 
change over the 15 year period in Tayside, Scotland.  Among the three papers of low 
quality, Galimberti et al (42) only compared the number of patients who were 
prescribed gabapentin and pregabalin between two years, 2000 and 2012, but again did 
not present the changes during the 12 year period.  The patients who were identified 
as being prescribed gabapentinoids in 2000 were from an earlier study conducted by 
the same researcher and this paper failed to report these details.  Thus, the results 
lacked validity and it was marked low quality.  Hollingworth et al (48) failed to give 
the sample size and details of study population and only examined two years, so again 
it lacked internal and external validity.  The final paper by Landmark et al (41) with 
low quality failed to give the information about the study population and data source, 




Table 4. Quality assessment of observational studies 
Assessment questions Baftiu et al (35) Nishtala et al (40) Baftiu et al (38) 
1. Was the research question or objective in this paper clearly stated? Y Y Y 
2. Was the study population clearly specified and defined? Y Y Y 
3. Were the study participants adequately described? For example, look for adequate descriptive data on age, 
sex, baseline health status, and other relevant variables. 
N N Y 
4. Were all the subjects selected or recruited from the same or similar populations (including the same time 
period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all 
participants? 
Y Y Y 
5. Were objective, standard criteria used for measurement of condition? Y Y Y 
6. For exposures that can vary in amount or level, did the study examine different levels of the exposure as 
related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 
Y Y Y 
7. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
8. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
9. Were the measures used in the study the most relevant ones for answering the research question? Y Y Y 
10. Was the study long enough, and large enough to allow changes in the outcome of interest to be identified? Y Y Y 
11. Was the outcome assessment blind to exposure status?  Y Y Y 
Other comments The study population only 
included people aged 60 or 
over; The results failed to 
give the exact value. 
The study population only 
included patients aged 65 or 
over; 
It failed to give the 
exact value, only gave 
the bar chart. 
Overall quality rating M M H 




Table 4 cont`d. Quality assessment of observational studies 
Assessment questions Italiano et al (32) Wettermark et al (8) Ruscitto et al (33) 
1. Was the research question or objective in this paper clearly stated? Y Y Y 
2. Was the study population clearly specified and defined? Y Y Y 
3. Were the study participants adequately described? For example, look for adequate descriptive data on age, 
sex, baseline health status, and other relevant variables. 
Y Y Y 
4. Were all the subjects selected or recruited from the same or similar populations (including the same time 
period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all 
participants? 
Y Y Y 
5. Were objective, standard criteria used for measurement of condition? Y Y Y 
6. For exposures that can vary in amount or level, did the study examine different levels of the exposure as 
related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 
Y Y Y 
7. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
8. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
9. Were the measures used in the study the most relevant ones for answering the research question? Y Y Y 
10. Was the study long enough, and large enough to allow changes in the outcome of interest to be identified? Y Y N 
11. Was the outcome assessment blind to exposure status?  Y Y Y 
Other comments   It only reported the 
rates of prescribing for 
two years 
Overall quality rating H H M 





Table 4 cont`d. Quality assessment of observational studies 
Assessment questions Hsieh et al (39) Hollingworth et al (37) Alacqua et al (31) 
1. Was the research question or objective in this paper clearly stated? Y Y Y 
2. Was the study population clearly specified and defined? Y Y Y 
3. Were the study participants adequately described? For example, look for adequate descriptive data on age, 
sex, baseline health status, and other relevant variables. 
N N Y 
4. Were all the subjects selected or recruited from the same or similar populations (including the same time 
period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all 
participants? 
Y Y Y 
5. Were objective, standard criteria used for measurement of condition? Y Y Y 
6. For exposures that can vary in amount or level, did the study examine different levels of the exposure as 
related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 
Y Y Y 
7. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
8. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
9. Were the measures used in the study the most relevant ones for answering the research question? Y Y Y 
10. Was the study long enough, and large enough to allow changes in the outcome of interest to be identified? Y N N 
11. Was the outcome assessment blind to exposure status?  Y Y Y 
Other comments Only including the patients who 
prescribed gabapentin for at least 
two times; prevalence only showed 
read by bar chart, lack of exact value. 
lack of sample size and 
age information; only 
studied only three or 
two years. 
The study period only 
last for 3 years for 
gabapentin, while only 
one year for pregabalin 




*Y yes, N no, H high quality, M mediate quality, L low quality, NA not applicable, NR not reported 
Table 4 cont`d. Quality assessment of observational studies 
Assessment questions Oteri et al (34) Savica et al (36) Landmark et al (41) 
1. Was the research question or objective in this paper clearly stated? Y Y Y 
2. Was the study population clearly specified and defined? Y Y Y 
3. Were the study participants adequately described? For example, look for adequate descriptive data on age, 
sex, baseline health status, and other relevant variables. 
N Y N 
4. Were all the subjects selected or recruited from the same or similar populations (including the same time 
period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all 
participants? 
Y Y Y 
5. Were objective, standard criteria used for measurement of condition? Y Y Y 
6. For exposures that can vary in amount or level, did the study examine different levels of the exposure as 
related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 
Y Y Y 
7. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
8. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
9. Were the measures used in the study the most relevant ones for answering the research question? Y Y Y 
10. Was the study long enough, and large enough to allow changes in the outcome of interest to be identified? Y Y Y 
11. Was the outcome assessment blind to exposure status?  Y Y Y 
Other comments The study population 
only included people 
aged over 65 
 There was no information about the 
study population and sample size; 
It failed to give the data source and 
the exact value for DDDs 




*Y yes, N no, H high quality, M mediate quality, L low quality, NA not applicable, NR not reported. 
Table 4 cont`d. Quality assessment of observational studies 
Assessment questions Galimberti et al (42) Hall et al (46) Marlow et al (45) 
1. Was the research question or objective in this paper clearly stated? Y Y Y 
2. Was the study population clearly specified and defined? Y Y Y 
3. Were the study participants adequately described? For example, look for adequate descriptive data on age, 
sex, baseline health status, and other relevant variables. 
N N N 
4. Were all the subjects selected or recruited from the same or similar populations (including the same time 
period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all 
participants? 
Y Y Y 
5. Were objective, standard criteria used for measurement of condition? Y Y Y 
6. For exposures that can vary in amount or level, did the study examine different levels of the exposure as 
related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 
Y Y Y 
7. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
8. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y Y 
9. Were the measures used in the study the most relevant ones for answering the research question? Y Y Y 
10. Was the study long enough, and large enough to allow changes in the outcome of interest to be identified? N Y Y 
11. Was the outcome assessment blind to exposure status?  Y Y Y 
Other comments It only included a two-year 
prescribing trend and it 
failed to give the details 
about earlier year; 
The study population only 
included patients who 
commence pregabalin or 
gabapentin. 
The study population 






Overall quality rating L M M 
*Y yes, N no, H high quality, M mediate quality, L low quality, NA not applicable, NR not reported. 
Table 4 cont`d. Quality assessment of observational studies continue 
Assessment questions Kwok et al (44) Leong et al (43) 
1. Was the research question or objective in this paper clearly stated? Y Y 
2. Was the study population clearly specified and defined? Y Y 
3. Were the study participants adequately described? For example, look for adequate descriptive data on age, sex, baseline 
health status, and other relevant variables. 
Y Y 
4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were 
inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? 
Y Y 
5. Were objective, standard criteria used for measurement of condition? Y Y 
6. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the 
outcome (e.g., categories of exposure, or exposure measured as continuous variable)? 
Y Y 
7. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all 
study participants? 
Y Y 
8. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all 
study participants? 
Y Y 
9. Were the measures used in the study the most relevant ones for answering the research question? Y Y 
10. Was the study long enough, and large enough to allow changes in the outcome of interest to be identified? Y Y 
11. Was the outcome assessment blind to exposure status?  Y Y 
Other comments The generalizability for the 
results is restricted to the 
elderly with low 
socioeconomic status. 
It failed to give the exact value for 
prevalence and the prevalence could 





Overall quality rating M H 
*Y yes, N no, H high quality, M mediate quality, L low quality, NA not applicable, NR not reported. 




2.4. Discussion  
The number of gabapentinoids prescriptions increased from 1 million in 2004 to 10.5 
million in 2015 in England and Wales (26).  In Scotland, according to the Information 
Services Division (ISD) electronic data, the number of pregabalin prescription items 
increased significantly from 27,094 in 2006 to 435,498 in 2016, while the number of 
gabapentin prescription items decreased slightly from 308,313 in 2010 to 302,736 in 
2011, then rose up to 694,293 in 2016.  In this systematic review, it was found that the 
prescribing rates and trends differed in different countries (Figure 2-a and Figure 2-b).   
The number of patients prescribed at least one gabapentin increased in UK (46), Taiwan 
(39) and Italy (42) during their study periods, while three other papers in Italy (31,32,34) 
found the incidence of gabapentin prescribing decreased in each of their study periods 
(Figure 2-a).  Two papers from Norway (38,41) found the numbers of DDDs of 
gabapentin increased during their study periods, while another Norwegian paper (35) 
found this decreased dramatically from 1.1 in 2007 to 0.25 in 2009 among patients with 
epilepsy (per 1,000 persons per day).  The study in New Zealand (40) found the 
number of DDDs of gabapentin increased from 0.35 in 2005 to 1.58 in 2008 and 
decreased to 0.04 in 2013.  In contrast, the study in Norway (35) found gabapentin 
prescribing increased dramatically from 0.2 DDD per 1,000 persons in 2004 to 3.5 in 
2013 among patients with neuropathic pain (Figure 2-a).   
The number of patients prescribed pregabalin at least once increased to differing extents 
in the UK and Italy, while it fluctuated in USA (Figure 2-b).  Studies in Australia (37) 
and Norway (35) both found the pregabalin DDD rates increased during their respective 
study periods.  Three papers (8,33,44) reported the rate of patients who were 
prescribed pregabalin and they all found the rate increased in their respective study 
periods.  However, the prevalence and incidence of pregabalin prescribing in Italy 
fluctuated (34) (Figure 2-b).   




the study population reported in these papers were different, such as general population, 
population with specific age ranges, population with specific diseases and populations 
who were prescribed at least one AED.  Secondly, the variables used to quantify 
gabapentinoids prescribing also varied from study to study, including numbers of DDDs, 
prevalence, number of patients, the proportion of patients and incidence.  Additionally, 
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There were three studies undertaken in Norway (35,38,41).  Two papers included the 
numbers of DDDs of gabapentin prescribed from 2004 to 2006, although their study 
periods were nine years (41) and 12 years (35).  The paper written by Landmark et al 
(41) reported that the number of DDDs of gabapentin increased from 0.8 in 2004 to 1 
in 2005 and then decreased to 0.9 in 2006 (per 1,000 persons per day), while the paper 
written by Arton Baftiu et al (35) reported that the number of prescribed DDDs of 
gabapentin increased from 0.2 in 2004 to 0.4 in 2006 for neuropathic pain patients and 
decreased from 1.25 in 2004 to 1.15 in 2006 for epilepsy patients (per 1,000 persons 
per day).  The difference is mainly due to the study population, one studying the whole 
population (41), the other studying people who were aged over 60 years old (35).  
Additionally, the study compared the number of prescribed DDDs of gabapentin among 
patients with neuropathic pain, epilepsy and psychiatry (35), while the other one 
calculated the number of prescribed DDDs of gabapentin among all patients prescribed 
gabapentin at least once (41).  Landmark et al (41) reported the trends of gabapentin 
prescribing among the whole population in Norway from 1996 to 2014.  However, 
there was one limitation to this paper in that the results were shown graphically as a 
line chart, making it difficult to calculate exact values for DDDs each year.  The paper 
written by Baftiu and Landmark et al (38) reported that the number of prescribed DDDs 
of gabapentin increased from 0.75 per 1,000 persons in 2008 to 1.9 in 2012 in Norway.  
This paper studied all people in Norway and used the Norwegian prescription database, 
therefore the results could reflect the change in gabapentin prescribing in the 
Norwegian general population from 2008 to 2012, but it failed to give the exact values 
for DDDs each year. 
Two studies (43,44) in Canada were both cross-sectional time series study.  One 
written by Kwok (44) only reported the rate of pregabalin from 2006 to 2014 among all 
ODB-eligible individuals.  This study found that there was a great increase in 
pregabalin use from 1 in the first quarter of 2013 to 22 in the last quarter of 2014 (per 
1,000 persons), mainly because the policy on access to pregabalin changed from an 




study failed to assess the use of medication paid for out of pocket or by private insurance, 
so maybe the rate of pregabalin use was underestimated.  Additionally, the 
generalizability of the results in this study were restricted to the elderly with low 
socioeconomic status due to the database used, and the study population was eligible 
for public drug coverage.  Thus, part of the observed pregabalin use increase may have 
resulted from the fact that some patients switched from private insurance to public drug 
coverage.  The other paper written by Leong et al (43) compared the prevalence of 
gabapentin prescribing among non-epileptic patients and epileptic patients in Manitoba, 
Canada from 1998 to 2013.  The most striking finding in this paper was that the 
gabapentin use increased dramatically among non-epileptic patients.  It also found 
more than half of all AED users were using gabapentin in 2013.  It was postulated that 
the observed rise in gabapentin use was due to the fact that gabapentin was widely used 
for neuropathic pain, and potentially also abused (49).  In Canada, pregabalin was 
approved for neuropathic pain and fibromyalgia, but was not covered by public health 
plans (50).  Thus, the restricted access to pregabalin may have also resulted in the rise 
of gabapentin use for pain conditions.  This study is of high quality, so it can represent 
the prevalence of gabapentin prescribing in the general population in Manitoba, Canada 
during 1998 to 2013.  A similar instance was noted by Hsieh et al in Taiwan (39) in 
that the proportion of patients prescribed gabapentin rose significantly among patients 
with neuropathic pain, while it was quite stable among epileptic patients.  This study 
also found that the number of gabapentin prescriptions increased gradually amongst the 
older group aged 55 or older, probably because gabapentin was used for pain disorders 
and pain disorders are common among older people (51).  However, this study only 
included patients who were prescribed at least two AEDs from 2003 to 2007, so the 
patients who only received one prescription were excluded.  Thus, the exact number 
of gabapentin users each year was underestimated and the actual trends in the 
proportion of gabapentin prescribing may be a little different from that among a general 
population in Taiwan from 2003 to 2007. 




periods and different populations, in addition to various independent variables used, it 
is difficult to synthesize the results.  However, it is interesting that one paper (32) 
reported that the incidence of gabapentin prescribing in 2011 was much lower than that 
in 2005 among each group of patients with epilepsy, pain and psychiatry in Caserta, 
Italy.  Especially for patients with pain disorder, the incidence decreased almost 7-fold 
in 2011 (7.3 per 1,000 persons) compared with 2005 (47 per 1,000 persons).  This 
study also found that the number of gabapentin prescriptions peaked in 2006 and then 
decreased from 2007, probably because of the endorsements of a health policy measure 
(Nota4) (26).  From 2007, in Italy, all AEDs were reimbursed by the National Health 
Service for all indications, while gabapentin was only free for epilepsy or severe 
neuropathic pain from post-herpetic neuralgia, diabetic neuropathy or cancer (52).  
The most striking point the study (32) found was that the trends of gabapentin and 
pregabalin prescribing were mutually dependent.  It seems that the decrease in 
gabapentin prescribing was balanced by the increase in pregabalin prescribing in the 
corresponding years, probably because gabapentin and pregabalin are made by the same 
company, prescribed for similar indications, and gabapentin use was influenced by the 
promotion strategy of pregabalin (53,54).  This study is of high quality, though it only 
studied the population aged 15 years old or older.  Another paper (34) also found the 
incidence of gabapentin prescribing decreased from 2004 to 2007 in Caserta.  
However, this study only selected patients aged 65 or over, using outpatient data, so the 
incidence of gabapentin prescribing may be underestimated.  Thus, these results 
cannot be generalized to the general population in Italy. 
Interestingly, one study in Sweden (8) found that pregabalin was dispensed more 
frequently to women than to men in Stockholm each year from 2006 to 2009, which 
was opposite to a Jordan study where 71.4% were males among the study population 
from November 2016 to January 2017 (55).  However, the study in Jordan only 
included 77 patients requesting pregabalin and the study period was quite short.   




studies had obvious limitations, so their results could not be generalized to the general 
population.  The most common limitations of these included papers without high 
quality was the study population with specific age ranges, specific diseases, residence 
in nursing home or commencing gabapentin or pregabalin, which limited the relevance 
of these included papers to the research questions.  The study in UK (46) only included 
the patients with a first gabapentin or pregabalin prescription during the study period, 
and did not include the patients who were already being prescribed gabapentinoids.  
Thus, the results are likely to be an underestimate compared with the actual number of 
patients who were prescribed gabapentin or pregabalin each year in the UK from 2006 
to 2010.  The paper from the USA (45) reported the trends of pregabalin prescribing, 
but the trends could not reflect the pregabalin prescribing trends in the general 
population in South Carolina, because this study included only a fibromyalgia cohort 
in which the pregabalin prescribing was likely to have been very different from a 
population with other diseases.  Additionally, in this paper, the number of patients 
prescribed pregabalin was calculated from baseline characteristics, and therefore did 
not include the number of patients who were prescribed pregabalin during the follow 
up period.  Five studies (34,35,40,42,44) were restricted to an elderly population and 
one study in Australia (37) had a lack of details about the study population.  Thus, 
these papers could not reflect the trends of gabapentin or pregabalin in the general 
population.   
Among the five papers of high quality, the study periods of four studies (8,32,36,38) 
were 2008-2012 (38), 2005-2011(32), 2005-2009 (8) and 2000-2005 (36), while one 
(43) studied gabapentinoids use from 1998 to 2013.  However, this study (43) only 
studied pregabalin and calculated the prevalence of pregabalin prescribing among 
epileptic patients and non-epileptic patients separately, so it did not report the total 
prevalence of pregabalin prescribing among the population being studied.  The results 
of this study were shown graphically by a line chart, so it failed to give the exact values 
for the prevalence of pregabalin.  In addition, it did not study pregabalin use in the 




gabapentin and pregabalin prescribing in recent years is required in the future. 
Strengths and limitations 
This systematic review has some strengths.  Firstly, this study is the first systematic 
review of the rates and trends of gabapentin and pregabalin prescribing in a general 
population.  Previous studies are either observational studies or reviews of gabapentin 
or pregabalin misuse.  Thus, this study is the first one to summarise the current 
published evidence on gabapentinoids prescribing trends.  Secondly, this study 
conducted quality assessments for each citation included in the review and analysed the 
strengths and limitations of these citations.  The quality assessment tool was not an 
existing tool but modified from several quality assessment tools on observational 
studies.  The quality assessment was also influenced by the other comments listed on 
the quality assessment table, making the assessment more comprehensive.  Thirdly, 
this systematic review was conducted with a strict systematic approach.  The selected 
databases were all authoritative and commonly used for searching medical papers or 
medicine related papers.  The combination of these databases contains most published 
English language papers related to the study topic with reference list manual checking 
also conducted.  The selection criteria were assessed and modified several times prior 
to use.  The paper selection was conducted in strict accordance using the selection 
criteria by two independent reviewers, which was effective to reduce the selector bias.  
Finally, the search strategy used MeSH terms in combination with free text, which made 
the search more efficient and comprehensive. 
However, the biggest limitation of this study is that this review only selected peer-
reviewed studies, with grey literature being excluded, as it is difficult to extract and 
integrate data from grey literature due to the heterogeneity and it is also hard to assess 
the quality of grey literature (56).  Another limitation was that after quality assessment, 
papers of low quality (37,41,42) were not excluded.  The study population of some 
papers does not represent the general population, but they were also included in the 




people or patients with epilepsy which was relevant to our research question.  
However, this may reduce the power of the systematic review and make the results from 
these papers difficult to synthesize, but inclusion of these papers was due to a limited 
amount of published papers studying the trends of gabapentinoids prescribing in a large 
population.  There was still a language bias, because we only can read English and 
Chinese.  After searching the key databases, all papers were written in English, 
without any Chinese papers, while after paper selection, there was one paper from 
Taiwan (39) written by Chinese researchers but written in English.  Finally, the 
heterogeneity in study characteristics and reporting made synthesis and direct 
comparisons difficult or impossible. 
2.5. Conclusion 
A comprehensive systematic review was conducted and 17 papers were included and 
underwent quality assessment.  After the results from these papers were summarised, 
the trends of gabapentin and pregabalin prescribing rates varied between different 
countries.  Because of the limitations of these papers, a further and more 
comprehensive epidemiological study focusing on the general population over a 
prolonged period is needed to identify the trends of gabapentin and pregabalin 
prescribing rates in a general population.  Ideally, this should include data from the 
time that the gabapentin or pregabalin were introduced to market to the latest year.  
The aims of this epidemiological study should include identification of rates of 
gabapentinoids prescribing during these years, factors associated with gabapentinoids 
prescribing (clinical, socio-demographic, patient/professional), and outcomes (benefits 
and harms). This information could provide evidence for identifying the reasons for 
rising gabapentinoids prescribing, and the effects of this, so that the appropriate policy 





3. Data analysis 
3.1. From the systematic review to data analysis 
The systematic review found that the trends of gabapentin and pregabalin prescribing 
differed in different countries.  These papers within the systematic review did not 
study the same period or same years.  The variables used to evaluate the gabapentin 
or pregabalin prescribing also varied from paper to paper, such as number of DDDs per 
1,000 persons per year (31,34,35,37,38,40,41), prevalence (34,36,43), incidence 
(31,32,34), the number of patients (39,42,45,46) and the proportion of patients 
(8,33,44).  Thus, the results of these papers could not be synthesized appropriately.  
Additionally, only five papers (8,32,36,38,43) within the review were of high quality.  
However, there were some limitations even to these five papers.  Firstly, two papers 
(38,43) reported the trends by line and bar charts, failing to show the exact values.  
Secondly, the study periods of three papers (8,32,38) were 2008 – 2012, 2005 – 2011 
and 2005- 2009 respectively.  They did not summarise the change in trends of 
gabapentinoids use in recent years.  The other paper written by Savica et al (36) only 
studied the prevalence of gabapentinoids prescribing from 2000 to 2005, failing to 
report the prevalence after 2005 and show the change of gabapentin prescribing after 
pregabalin was marketed in 2005.  Thirdly, the paper by Leong et al (43) summarised 
the prevalence of gabapentin prescribing from 1998 to 2013, but it gave the change of 
prevalence among epileptic patients and non-epileptic patients separately, so it failed to 
summarise the prescribing trends for the whole population.  Thus, there was a need to 
conduct a further study to summarise the trends of gabapentin and pregabalin 
prescribing in recent years among a general population.  
In Scotland, there has been a significant increase in the number of gabapentin and 
pregabalin prescriptions, seen by summarising the prescribing data from the ISD 
website (57).  However, there is no published evidence on the number of patients who 
were prescribed gabapentin or pregabalin each year in Scotland nor the total number of 




Additionally, the evidence on whether the gabapentinoids prescribing is associated with 
demographic factors and health outcomes, such as cancer, death, outpatient health 
service use, accident and emergency service use, is also limited. 
In 2013, the number of deaths associated with pregabalin significantly increased from 
2013 (19 deaths) to 2014 (38 deaths) in the UK (24).  The number of deaths associated 
with gabapentin also climbed up from 17 in 2013 to 26 in 2014 (24).  The number of 
death certificates in which gabapentinoids were cited significantly grew from less than 
1 per year prior to 2009 to 137 in 2015 in England and Wales (26). 
Thus, part two of this work would address the gaps found by the systematic review, 
aiming to summarise the prescribing rates and trends of gabapentinoids in Tayside over 
11 years (2006-2016) and Fife over seven years (2010-2016) and investigate their 
associations with demographic factors and the use of health services.  This study 
would be the first one to investigate gabapentinoids prescribing rates in Tayside and 
Fife over recent years.  It aims to provide epidemiological evidence on the patterns of 
gabapentin and pregabalin prescribing to allow policy makers (such as NHS Tayside 
and the Scottish Government) to make fitting policy changes to make the prescribing 
of these drugs more appropriate.  Additionally, it is hoped this study will provide 
useful evidence for further studies. 
3.2. Methods 
3.2.1. Ethics and permission 
The data for this study were provided by the “Safe Haven” platform from the Health 
Informatics Centre (HIC) at the University of Dundee.  The current version of the HIC 
Data User Declaration (DUD) was signed and the MRC E-course 'Research Data and 
Confidentiality' was completed by the author and supervisors. 
The server “Safe Haven” is used to protect data confidentiality, providing a restricted 
and secure IT environment.  In such an environment, users cannot export data out of 




statistics software and undertake analysis on the server.  Results cannot be released 
externally without approval of HIC administrators. 
3.2.2. Data management 
3.2.2.1. Data source 
The large dataset and data-linkage for this study were prepared by HIC, including 
datasets of routine health and administrative data, reporting: prescriptions, demography, 
cancer registrations, death registrations, Accident and Emergency attendances (A&E), 
and hospital admissions.   
The prescribing dataset consists of gabapentin or pregabalin prescriptions in Tayside 
from 2006 to 2016 and Fife from 2010 to 2016.  It contains the details of each 
prescription dispensed, recording the prescribed date, the drug name, the strength, the 
quantity of drug dispensed, the instruction for taking prescribed medicine, the unique 
number of the drug, and the health board.  The medicines, gabapentin and pregabalin, 
are identified by the British National Formula (BNF) code of 4.8.1. 
The demography file consists of 63,253 single records coming from the national CHI 
dataset, recording the demographic details for patients in Tayside and Fife health boards.  
This is based on the Community Health Index (CHI), which attributes a unique number 
to every individual who is registered with the NHS in Scotland.  The demographic 
factors include gender, age (= 2017-the year patient was born), Health Board area of 
NHS registration, rurality and the Scottish Index of Multiple Deprivation (SIMD).  
SIMD is classified into five quintiles to reflect the socioeconomic level and SIMD1 
represents the most deprived quintile.  Rurality with six groups was recorded in 
accordance with the Scottish Government 6-fold Urban Rural Classification: large 
urban, other urban areas, accessible small towns, remote small towns, accessible rural 
and remote rural. 
The death dataset includes all deaths registered in all Health Boards areas in Scotland 




Classification of Diseases, 10th edition (ICD-10).  The cancer registration dataset 
records all incidences of cancer registered in 2016 in Tayside and Fife Health Boards.  
The hospital admissions datasets, A&E dataset and outpatient dataset only contain 
attendances that occurred in 2016 in all Health Boards of Scotland.   
The Data-linkage focuses on data recorded in 2015 and 2016 (Figure 3).  All the 
datasets were linked by matching the Pro-CHI of the patient.  The Community Health 
Index (CHI) is used as a unique personal identifier allocated for each patient on first 
registration with GP practices in Scotland. Pro-CHI is an anonymized number for CHI 
created by the HIC analysts to protect personal information.   
The number of gabapentin and pregabalin prescriptions in Scotland and the total 
number of people in Tayside, Fife and Scotland originated from Information Services 
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3.2.2.2. Data cleaning and grouping 
GP Prescribing dataset (Tayside 2006-2016, Fife 2010-2016) 
Excel was used to manage this dataset.  First, the dataset was cleaned by removing the 
duplicate cases.  Duplications were defined as cases that were the same in all of seven 
variables, ProCHI, Corrected prescribing date, Res-seqn which is the drug identifier, 
quantity, drug name, strength, and health board.  Second, according to the corrected 
prescribed date, the prescriptions of gabapentin and pregabalin in the same year were 
selected into tables.  As the data were not presented as expected, organized as a form 
of each prescription with Pro-CHI, and several rows referring to different dates for one 
patient, a pivot table was used to summarise the counts of prescriptions for each patient 
every year.  Thus, by using the pivot tables, the reconfigured dataset presents a single 
record for each patient and the record contains the counts of gabapentin and pregabalin 
prescriptions per year for each patient, called Dataset 1 which would be used to 
summarise the trends of gabapentin and pregabalin prescribing from 2006 to 2016.  
For 2015 and 2016 data the pivot tables were merged into one dataset with the cases 
missing Pro-CHI being deleted.  The merged dataset had five new variables created: 
patients prescribed gabapentin or pregabalin in 2015; patients prescribed gabapentin or 
pregabalin in 2016; patients prescribed gabapentin or pregabalin in both years; patients 
prescribed both pregabalin and gabapentin in 2015; and patients prescribed both 
pregabalin and gabapentin in 2016.  This merged dataset was called Dataset 2 which 
would be used to link the other demographic and health outcome datasets. 
For the other six datasets being linked, firstly, the duplications were checked and 
removed for each, then each dataset was managed as described below. 
Demography file 
The demographic file reports age as a continuous variable calculated until the end of 
2017.  This variable was re-categorized into five age groups: 0-17, 18-40, 41-60, 61-




groups, children and the extreme elderly, 0-17 and 80+ became two independent groups.  
People aged between 18 and 80 were divided into three groups with a 20-year interval. 
SMR06 Cancer register 
Pivot tables were used to summarise the episodes of cancer for each patient.  The 
patients were categorized into two groups: without cancer episode, and with at least one 
cancer episode. 
GRO Death dataset 
The underlying cause of death was presented as ICD-10 codes by HIC for applicable 
patients.  This study grouped the underlying cause of death coded by ICD-10 as 
follows. 
1. Disease of circulatory system (I00-I99) 
1.1 Acute myocardial infarction (I21, I22, I23) 
1.2 Ischaemic heart disease including angina (I20, I24, I25) 
1.3 Cerebrovascular disease (I60-I69) 
2. All neoplasm (C00-D48) 
2.1 Neoplasms of the digestive organs (C15-C26) 
2.2 Neoplasms of the respiratory and intrathoracic organs (C30-C39) 
3. Disease of respiratory system (J00-J99) 
3.1 Pneumonia (J12-J18) 
3.2 Chronic lower respiratory disease (J40-J47) 
4. Disease of digestive system (K00-K93) 
5. Disease of the nervous system (G00-G99) 




SMR01 Hospital admissions dataset 
Pivot table function was used to summarise the counts of attendance, average length of 
hospital stay, as well as minimum and maximum length of stay for each patient. 
Accident & Emergency dataset 
Pivot table was used to summarise the counts of attendance for each patient. 
SMR00 Outpatient appointment 
Pivot table was used to summarise the counts of appointments for each patient 
according to the clinical date of attendance. 
3.2.2.3. Data linkage 
Dataset 2 was linked with all other cleaned and grouped datasets by matching Pro-CHI 
in Excel using the VLOOKUP function.  VLOOKUP is a built-in function in excel to 
lookup and retrieve data from a specific column in a table and it supports approximate 
and exact matching.  Lookup values must appear in the first column of the table, with 
lookup columns to the right. 
=VLOOKUP (Value you want to look up, range where you want to lookup the 
value, the column number in the range containing the return value, Exact Match 
or Approximate Match – indicated as 0/FALSE or 1/TRUE) 
3.2.3. Data analysis 
3.2.3.1. Descriptive analysis 
The frequencies of gabapentin prescriptions, pregabalin prescriptions, patients who 
were prescribed at least one gabapentin and patients who were prescribed at least one 
pregabalin in each year in each health board, Tayside and Fife, were summarised.  In 
one day, for the same patient, the prescriptions of the same medicine would be counted 




and res-seqno which is the drug identifier.  To specifically evaluate the trends of 
gabapentin and pregabalin prescribing in Tayside, Fife and Scotland, six calculations 
were conducted as follows. 
1. The number of patients who received at least one gabapentin prescription each 
year in Tayside (2006 to 2016) and Fife (2010 to 2016) separately. 
2. The number of patients who received at least one pregabalin prescription each 
year in Tayside (2006 to 2016) and Fife (2010 to 2016) separately. 
3. The total number of gabapentin prescriptions each year in Tayside (2006 to 2016) 
and Fife (2010 to 2016) separately. 
4. The total number of pregabalin prescriptions each year in Tayside (2006 to 2016) 
and Fife (2010 to 2016) separately. 
5. The gabapentin or pregabalin prescribing rate is calculated as (No.1 or No.2*100) 
divided by the total population in corresponding health board per year, with the 
unit (%). 
6. The average number of gabapentin or pregabalin prescriptions per 1,000 persons 
is calculated as (No.4 or No.5 *1,000) divided by the total population in 
corresponding health board per year.  
The data in relation to the number of gabapentin and pregabalin prescriptions in 
Scotland each year from 2006 to 2016 was collected from the Information Services 
Division (ISD) website (57) and the total of the Scottish population for each of these 
years was gathered from available data on the National Record of Scotland (NRS) 
website (58).  This allowed the average number of gabapentin and pregabalin 
prescriptions per 1,000 persons in Scotland to be calculated, which could then be 
compared with the figures in Tayside and Fife. 
SPSS version 22 statistical software programme was used to summarise the 




and 2016 in relation to demographic factors: gender, age, SIMD, rurality and Health 
Board.  Descriptive analyses for cancer, death, underlying cause of death, outpatient 
appointments, hospital admissions and A&E were also conducted.  Population 
pyramid figures were used to describe the distribution patterns of the total counts of 
gabapentin and pregabalin prescriptions each individual person received in both 
Tayside and Fife per year in 2015 and 2016, and potential differences between female 
and male patients were also calculated. 
3.2.3.2. Age standardisation 
Age standardisation can allow for the difference of age structures of populations and 
age standardised mortality can make the mortalities directly comparable in different 
populations which are different in age structure.  To compare the age standardised 
mortality of the gabapentinoids prescribing population with Scottish national age 
standardised mortality data from the NRS website, the age of this study population was 
re-categorised into 19 groups to match the NRS categories with a 5-year interval, such 
as 0-4, 5-9, 10-14 up to 90+.  The underlying cause of death was divided into three 
groups, circulatory deaths, respiratory deaths and all other deaths to match the NRS 
categories.  The frequency of patients who were prescribed at least one gabapentinoid 
in 2015 and 2016 in each age group were summarised.  In this study population, the 
counts of deaths in each age group in 2015 and 2016 were also summarised.   
The standard population used was the 2013 European Standard Population (ESP) and 
this was applied to the Scottish national age standardised mortality calculation in 2015 
and 2016.  The formula provided from the Office for National Statistics was used to 
calculate the age standardised mortality of this study population. 
Age standardised Mortality = ∑(pk mk) / ∑pk 
pk = the number of people of the standard population in age group (ESP) 
mk = observed mortality rate (per 100,000) in age group 




The age standardised mortality in this study was an average standardised death rate for 
two years, 2015 and 2016.  The average Scotland standardised mortality for 2015 and 
2016 was equal to the mean of the Scottish standardised mortalities in 2015 and 2016.  
The age standardised mortality rate was calculated for each of the underlying causes of 
death and the total number of deaths.  Relative risk and 95% confidence intervals were 
calculated for each age standardised mortality rate by OpenEpi, version 3.01.  
OpenEpi is a free, web-based and open source software for use in epidemiologic 
statistics. 
3.2.3.3. Regression 
This study used two types of regression model to examine the association of 
gabapentinoids prescribing and demographic factors.  The first is a logistic regression 
model used to investigate what demographic factors were likely to be associated with 
the prescribing of gabapentin or pregabalin.  The second is the Poisson model used to 
examine which demographic factors would be associated with an increase in the 
number of gabapentin or pregabalin prescriptions among patients who had already been 
prescribed gabapentin or pregabalin at least once. 
Logistic regression model 
Logistic regression modelling is used to test the association between a binary outcome 
and one or more factors.  In this study, the population studied by the logistic regression 
model was patients who had been prescribed only gabapentin or only pregabalin each 
year, so these patients who had been prescribed both gabapentin and pregabalin in the 
same year would not be analysed by the logistic regression model.  In the model, 
prescribed pregabalin is the positive outcome and prescribed gabapentin is the negative 
outcome, and logistic regression modelling was fitted to evaluate the association 
between the outcome and the demographic factors of interest in each year, 2015 and 
2016.  The demographic factors included age group, SIMD, gender, health board and 




categorical variables with the reference category being defined as the group with largest 
numbers; age 41-60; female; Tayside; and other urban groups were set as reference 
categories.  SIMD1 represents the most deprived areas, so it was chosen as the 
reference category.  The significance level was set as 0.05 (ɑ = 0.05) which means 
there was a 5% risk to reject the null hypothesis when it was actually true.  The enter 
tool was used in each model, because this study was not to produce a prediction model 
but just to examine the associations.  Thus, the factors which were not significant 
would also be kept in the model.  The fitted logistic regression model is shown as 
follows; 
Prescribed ~ Age + Gender + SIMD + Rurality group + Health board 
Prescribed indicates that pregabalin were prescribed and gabapentin was not prescribed. 
The odds ratio and 95% confidence interval were calculated by SPSS.   
Poisson regression model 
In statistics, Poisson regression is a generalized linear model to count data and construct 
contingency tables.  In this study, the population studied by the model was patients 
who received at least one gabapentin or pregabalin each year.  The Poisson model was 
used to test the association between demographic factors and the count outcome: counts 
of gabapentin or pregabalin prescriptions per patient.  The independent demographic 
factors were age as a continuous factor, with gender, SIMD, rurality and Health Board 
entered as categorical factors.  The significance level was set as 0.05 (ɑ = 0.05) which 
means there was a 5% risk to reject the null hypothesis when it was actually true.  The 
Poisson model is constructed as below; 
Log (counts of gabapentin or pregabalin prescription) ~ Age + Gender + 




The coefficient of each subgroup of each factor is called estimated effect size which is 
related to relative risk (RR); 
eg. For gender, if female is the reference category, the coefficient of the male is X,  
then RR= exp (estimated effect size of male) = exp (X) 
exp(X) means if all the other covariates remain the same, the number of gabapentin or 
pregabalin prescribed in male group will be exp (X) times of that prescribed to reference 
category, female.  (exp (X)-1) *1000 means (exp (X)-1) *1000 more prescriptions of 
gabapentin or pregabalin in 1000 male patients than 1000 female patients. 
The reference category is the group with largest size.  Each model would keep all of 
these five independent factors, including significant and insignificant factors, because 
the model was not used for prediction, but for evaluation of association between 
variables. 
3.3. Results 
3.3.1. Data cleaning 
In the original prescribing dataset with 1,091,199 prescription records, 15,984 
duplications were identified and removed (Figure 4).  These pairs of duplicate cases 
had the same in Pro-CHI, drug identifier, strength, quantity, corrected prescribing date, 
drug name and health board.  There were 1,075,215 prescription records 
remaining,and these related to 57,842 patients (Figure 4). 
The prescription records in the same year were selected into the same table according 
to corrected prescribing date.  In 2015, the prescribing table included 26,740 patients, 
61,658 pregabalin prescriptions and 114,023 gabapentin prescriptions.  In 2016, the 
prescribing table included 29,233 patients, 73,791 pregabalin prescriptions and 122,713 
gabapentin prescriptions.  The two tables were merged into Dataset 2 to include a 
single entry for each individual patient, with 36,800 patients after deleting 214 patients 




There were 63,235 patients with information on Pro-CHI, gender, SIMD, Health board, 
rurality, date of birth, age (ended in 2017) and postcode in the demography file and no 
duplications were found.  The GRO death file contained 8,570 patients with an 
underlying cause of death coded with ICD-10.  The SMR06 Cancer register dataset 
contained 733 records and 721 patients after 47 duplications were identified and 
removed.  For the Hospital admission dataset, there were 42,287 records and 14,930 
patients.  The outpatient dataset contained 164,587 records and 36,852 patients after 
removing 1,293 duplications which were duplicated in Pro-CHI, specialty, location and 
clinic date (Figure 5). 
These seven datasets were merged into one new dataset, Dataset 3, matched with Pro-



















GP Prescribing dataset 
N= 1,091,199 prescriptions 
N= 1,075,215 prescriptions 
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2015 prescribing table 
pregabalin prescriptions: N=61,658 
gabapentin prescriptions: N=114,023 
patients: N=26,740 
2016 prescribing table 
pregabalin prescriptions: N=73,791 
gabapentin prescriptions: N=122,713 
patients: N=29,233 
Merge 
Pregabalin prescriptions: N=135,449 
Gabapentin prescriptions: N=236,736 
Patients: N=37,014 
Dataset 2 
Patients: N= 36,800 
214 patients without Pro-
CHI, removed 
Demography data 





Cleaned Cancer data  
















N= 13,312 patients 
Hospital admission data 











3.3.2. Descriptive analysis 
Cleaned GP Prescribing dataset 
The prescribing trends of gabapentin and pregabalin in Tayside, Fife and Scotland were 
specified as the changing number of prescriptions, number of patients, the proportions 
of patients and the average number of prescriptions per 1000 persons for gabapentin 
and pregabalin respectively.   
In Scotland, the number of gabapentin prescriptions increased gradually from 2006 to 
2010 and then decreased slightly in 2011 and rose rapidly every year from 2012 to 
2016.  There were 694,293 gabapentin prescriptions in 2016 which was four times 
more than the 164,630 prescriptions in 2006.  In Tayside, the number of gabapentin 
prescriptions grew gradually from 16,481 in 2006 to 31,615 in 2010 and then 
decreased slightly in 2011 to 29,519 and increased again from 2011 to 2016 to 57,472.  
In Fife, the number of gabapentin prescriptions increased gradually from 20,645 in 
2010 to 65,241 in 2016 (Figure 6). 
 



































In Scotland, the number of pregabalin prescriptions dramatically climbed up from 2006 
(27,094) to 2016 (435,498, which is 16 times that of the figure in 2006).  In Tayside, 
the number of pregabalin prescriptions increased sharply from 2006 to 2016; the figures 
in 2016, 48,648, are approximately 21.5 times higher than that in 2006 (2,271).  In 
Fife, there was a gradual growth from 10,506 in 2010 to 25,143 in 2016 (Figure 7). 
 
 
Figure 7. The number of pregabalin prescriptions in Tayside, Fife and Scotland from 2006 to 2016 
 
The average number of gabapentin prescriptions per 1,000 persons in Scotland was 
lower than that in Tayside or Fife in the corresponding years: for Fife, the average 
number of gabapentin prescriptions rose dramatically from 2010 (57/1,000) to 2016 




































Figure 8. The average number of gabapentin prescriptions per 1000 persons in Tayside, Fife and 
Scotland from 2006 to 2016 
Pregabalin prescribing in Fife was lower than that in Tayside and Scotland before 2012.  
Pregabalin prescriptions increased gradually in Tayside and Scotland from 2006 to 2010 
and soared from 2010 to 2016.  In 2016 in Tayside (117/1,000), it was almost 20 times 
higher than that in 2006 (6/1,000) (Figure 9).    
 
Figure 9. The average number of pregabalin prescriptions per 1000 persons in Tayside, Fife and 







































































The number of patients receiving at least one gabapentin prescription increased in 
Tayside and Fife, with a four-fold increase during the 11 years in Tayside (Figure 10).  
While for pregabalin, the number of patients decreased very slightly in Fife in 2012 
before rising, for Tayside with the number of patients almost 15 times higher in 2016 
(6,564 patients) than that in 2006 (442 patients) (Figure 11). 
 
Figure 10. The total number of patients who were prescribed gabapentin at least once in Tayside and 
Fife from 2006 to 2016 
 
Figure 11. The total number of patients who were prescribed pregabalin at least once in Tayside and 
Fife from 2006 to 2016 





















































represents 0.7% to 2.27% of the total population in Tayside between 2006 to 2016 and 
1.47% to 3.04% of the total population in Fife between 2010 and 2016 (Figure 12).  
For pregabalin, the rate increased from 0.11% in 2006 to 1.58% in 2016 in Tayside and 
the rate ranged from 0.54% to 1.02% in Fife between 2010 and 2016. (Figure 13) 
 
Figure 12. The proportion of patients who were prescribed gabapentin at least once in the total 
population of Tayside and Fife from 2006 to 2016 
 
Figure 13. The proportion of patients who were prescribed pregabalin at least once in the total 




























































A total of 36,800 patients were prescribed gabapentinoids at least once in Tayside and 
Fife in 2015 and 2016.  Of these, 26,637 patients were recorded in 2015 and 29,122 
patients in 2016, with 18,959 patients prescribed gabapentinoids in both 2015 and 2016.  
The mean age of all patients prescribed a gabapentinoid during 2015 and 2016 was 
58.19 (SD 16.15) (Table 5).  Overall, only 46 patients (0.1%) were 17 years old or 
below and most patients (40.5%) were in the age group 41-60 years old; 62.4% of 
patients were female; and 53.6% of patients were resident in Tayside (Table 5).  
SIMD1 represents the most deprived quintile and SIMD5 is the least deprived quintile.  
The range of the proportion of patients amongst the five SIMD categories in 2015 and 
2016 was 12.1% to 22.9% (Table 5).  There were 16,324 patients (44.4%) resident in 
other urban area according to rurality code and 620 patients (1.7%) resident in a remote 
rural area in both 2015 and 2016 (Table 5).  In 2015, a total of 26,637 patients were 
prescribed a gabapentinoid at least once; of them, 17,814 patients (66.9%) were only 
prescribed gabapentin and 7,139 patients (26.3%) were only prescribed pregabalin 
(Table 5).  In 2016, a total of 29,122 patients were prescribed gabapentinoids at least 
once; 18,842 patients (64.7%) were only prescribed gabapentin and 8,503 patients 




Table 5. The demographic characteristics of patients who received at least one gabapentinoid in 2015 
and 2016 




Both 2015 and 
2016 (n=18,959) 
Total (n=36,800) 
Age (mean, SD) 58.73 (15.80) 57.95 (15.96) 58.58 (15.35) 58.19 (16.15) 
Age group     
 0-17 26 (0.1%) 34 (0.1%) 14 (0.1%) 46 (0.1%) 
 18-40 3,555 (13.3%) 4,296 (14.8%) 2,380 (12.6%) 5,471 (14.9%) 
 41-60 10,970 (41.2%) 12,110 (41.6%) 8,176 (43.1%) 14,904 (40.5%) 
 61-80 9,621 (36.1%) 10,158 (34.9%) 6,736 (35.5%) 13,043 (35.4%) 
 80+ 2,465 (9.3%) 2,524 (8.7%) 1,653 (8.7%) 3,336 (9.1%) 
Gender     
 Female  16,626 (62.4%) 18,238 (62.6%) 11,874 (62.6%) 22,990 (62.4%) 
 Male  10,011 (37.6%) 10,884 (37.4%) 7,085 (37.4%) 13,810 (37.5%) 
Health board     
 Tayside  14,077 (52.9%) 15,029 (51.6%) 9,989 (52.7%) 19,117 (53.6%) 
 Fife  12,560 (47.1%) 14,093 (48.4%) 8,970 (47.3%) 17,683 (46.4%) 
Scottish SIMD     
 SIMD1 6,311 (23.7%) 6,911 (23.7%) 4,789 (25.3%) 8,433 (22.9%) 
 SIMD2 5,780 (21.7%) 6,347 (21.8%) 4,282 (22.6%) 7,845 (20.3%) 
 SIMD3 4,921 (18.5%) 5,441 (18.7%) 3,437 (18.1%) 6,925 (18.8%) 
 SIMD4 5,426 (20.4%) 5,893 (20.2%) 3,708 (19.6%) 7,611 (20.7%) 
 SIMD5 3,161 (11.9%) 3,329 (11.4%) 2,025 (10.7%) 4,465 (12.1%) 
Rurality code     
 Large urban 6,129 (23.0%) 6,418 (22.0%) 4,468 (23.6%) 8,079 (22.0%) 
 Other urban 11,752 (44.1%) 13,042 (44.8%) 8,470 (44.7%) 16,324 (44.4%) 
 Accessible small town 2,854 (10.7%) 3,123 (10.7%) 1,962 (10.3%) 4,015 (10.9%) 
 Remote small town 455 (1.7%) 507 (1.7%) 309 (1.6%) 653 (1.8%) 
 Accessible rural  3,976 (14.9%) 4,366 (15.0%) 2,754 (14.5%) 5,588 (15.2%) 
 Remote rural 433 (1.6%) 465 (1.6%) 278 (1.5%) 620 (1.7%) 
Only gabapentin (number of 
patients) 
17,814 (66.9%) 18,842 (64.7%)   
Only pregabalin (number of 
patients) 
7,139 (26.8%) 8,503 (29.2%)   
Both prescribed (number of 
patients) 







A total of 19,498 patients in 2015 and 20,619 patients in 2016 were prescribed 
gabapentin in Tayside and Fife, including patients who were prescribed both pregabalin 
and gabapentin in the same year.  The mean age of patients was 59.01 and 58.31 in 
2015 and 2016 respectively; most patients were in the 41-60 years group (40.5% in 
2015 and 40.7% in 2016); 23 patients and 1,826 patients respectively were below 18 
years old and over 80 years old in 2015, while for 2016, 29 patients and 1,799 patients 
were respectively reported for these age groups (Table 6).  Female patients were 
prescribed gabapentin more frequently than males, 62.1% and 62.4% in 2015 and 2016 
respectively; most patients were from Fife (52.5% in 2015 and 54.4% in 2016) (Table 
6).  The smallest proportion of patients lived in SIMD5 in 2015 (11.7%), and the same 
with 2016 (11.4%) (Table 6).  The largest proportion of patients lived in Other urban 
area in 2015 and 2016 (46.9% and 47.7% respectively), while the smallest proportion 
lived in remote small towns (1.5% in 2015 and 1.4% in 2016) (Table 6).  There were 
1,684 patients prescribed both gabapentin and pregabalin in 2015 and 1,777 patients 
prescribed both gabapentin and pregabalin in 2016. 
In 2015, the average number of gabapentin prescriptions per person was 5.83, and the 
range was 1 to 36; the median was 5 (Table 6).  The number of gabapentin 
prescriptions per patient per year in 2015 was not normally distributed (Figure 14).  
Most patients received more than one prescription of gabapentin but the number of 
patients who received one prescription was largest in 2015 whether they were female 
or male patients (Figure 14).  The distribution pattern of the number of gabapentin 
prescriptions among male and female patients in 2016 was quite similar to that in 2015 












Table 6. The demographic characteristics of patients who received at least one gabapentin prescription 
in Tayside and Fife in 2015 and 2016 
 
 2015(N=19,498) 2016(N=20,619) 
Age (mean, SD) 59.01 (15.835) 58.31 (15.961) 
Age group   
 0-17 23 (0.1%) 29 (0.1%) 
 18-40 2,544 (13.0%) 2,937 (14.2%) 
 41-60 7,888 (40.5%) 8,402 (40.7%) 
 61-80 7,217 (37.0%) 7,452 (36.1%) 
 80+ 1,826 (9.4%) 1,799 (8.7%) 
Gender   
 Female 12,107 (62.1%) 12,859 (62.4%) 
 Male 7,391 (37.9%) 7,760 (37.6%) 
Health board   
 Tayside  9,259 (47.5%) 9,407 (45.6%) 
 Fife  10,239 (52.5%) 11,212 (54.4%) 
SIMD   
 Missing 738 (3.8%) 820 (4.0%) 
 SIMD1 4,803 (24.6%) 5,093 (24.7%) 
 SIMD2 4,305 (22.1%) 4,575 (22.2%) 
 SIMD3 3,585 (18.4%) 3,817 (18.5%) 
 SIMD4 3,793 (19.5%) 3,968 (19.2%) 
 SIMD5 2,274 (11.7%) 2,346 (11.4%) 
Rurality classification in Scotland   
 Missing 738 (3.8%) 820 (4.0%) 
 Large urban  4,081 (20.9%) 4,106 (19.9%) 
 Other urban 9,137 (46.9%) 9,828 (47.7%) 
 Accessible small town 2,140 (11.0%) 2,265 (11.0%) 
 Remote small towns 288 (1.5%) 289 (1.4%) 
 Accessible rural 2,811 (14.4%) 3,003 (14.6%) 
 Remote rural 303 (1.6%) 308 (1.5%) 
Average of prescription per person 5.83 (4.639) 5.94 (4.685) 
Number of prescriptions  113,723 122,445 
 Range 1-36 1-33 
 Mean 5.83 5.94 
 Mode 1 1 
 Median 5 5 
 25% percentile 2 2 
 50% percentile 5 5 





Figure 14. The distribution pattern of number of gabapentin prescriptions per patient per year, among 
those who received at least one prescription in Tayside and Fife in 2015 
 
Figure 15. The distribution pattern of number of gabapentin prescriptions per patient per year, among 
those who received at least one prescription in Tayside and Fife in 2016 




including patients who were prescribed both gabapentin and pregabalin in the same year.  
The mean age of patients was 57.71 and 56.68 in 2015 and 2016 respectively; most 
patients were in 41-60 years group (43.3% in 2015 and 43.9% in 2016); 5 patients and 
751 patients were below 18 years old and over 80 years old in 2015 respectively, while 
for 2016 the numbers for these corresponding age groups were 7 patients and 829 
patients (Table 7).  Female patients accounted for 63.6% and 63.4% of prescriptions 
in 2015 and 2016 respectively; most patients were from Fife (65.7% in 2015 and 63.7% 
in 2016) (Table 7).  The patients living in SIMD5 was the smallest proportion in 2015 
(12.2%), and the same with 2016 (11.5%) (Table 7).  The largest proportion of patients 
lived in Other urban area in 2015 and 2016 (37.6% and 38.8%), while the least 
proportion lived in remote rural area (1.9% in 2015 and 1.8% in 2016) (Table 7).   
In 2015, the average number of pregabalin prescriptions per patient was 6.97, and the 
range was from 1 to 37; the median was 6 (Table 7).  The number of pregabalin 
prescriptions per patient per year in 2015 was not normally distributed (Figure 16).  
Most patients received more than one prescription of pregabalin but the frequency of 
one prescription was the greatest in 2015 whether they were female or male patients 
(Figure 16), which was similar to the pattern of gabapentin prescriptions.  The 
distribution pattern on the number of pregabalin prescriptions among male and female 
patients in 2016 was quite similar with that in 2015 (Table 7, Figure 17).  The average 







Table 7. The demographic characteristics of patients who received at least one pregabalin prescription in 
Tayside and Fife in 2015 and 2016 
 2015 (N=8,823) 2016 (N=10,280) 
Age (mean, SD) 57.71 (15.677) 56.68 (15.914) 
Age group   
 0-17 5 (0.1%) 7 (0.1%) 
 18-40 1,277 (14.5%) 1,700 (16.5%) 
 41-60 3,825 (43.3%) 4,511 (43.9%) 
 61-80 2,965 (33.6%) 3,233 (31.5%) 
 80+ 751 (8.5%) 829 (8.1%) 
Gender   
 Female 5,610 (63.6%) 6,521 (63.4%) 
 Male 3,213 (36.4%) 3,759 (36.6%) 
Health board   
 Tayside 5,796 (65.7%) 6,546 (63.7%) 
 Fife 3,027 (34.3%) 3,734 (36.3%) 
SIMD   
 Missing 371 (4.2%) 462 (4.5%) 
 SIMD1 1,895 (21.5%) 2,270 (22.1%) 
 SIMD2 1,805 (20.5%) 2,166 (21.1%) 
 SIMD3 1,674 (19.0%) 1,938 (18.9%) 
 SIMD4 2,000 (12.7%) 2,262 (22.0%) 
 SIMD5 1,078 (12.2%) 1,182 (11.5%) 
Rurality classification in Scotland   
 Missing 371 (4.2%) 462 (4.5%) 
 Large urban  2,450 (27.8%) 2,743 (26.7%) 
 Other urban 3,314 (37.6%) 3,989 (38.8%) 
 Accessible small town 886 (10.0%) 1,059 (10.3%) 
 Remote small town 206 (2.3%) 233 (2.3%) 
 Accessible rural 1,426 (16.2%) 1,605 (15.6%) 
 Remote rural 170 (1.9%) 189 (1.8%) 
Average of prescription per person 6.97 (5.1) 7.16 (5.284) 
Number of prescriptions group 61,503 73,572 
 Range 1-37 1-52 
 Mean 6.97 7.16 
 Mode 1 1 
 Median 6 6 
 25% percentile 2 3 
 50% percentile 6 6 











Figure 16. The distribution pattern of the number of pregabalin prescriptions each patient had per year 
in Tayside and Fife, among those who received at least one prescription in 2015 
 
 
Figure 17. The distribution pattern of the number of pregabalin prescriptions each patient had per year 
in Tayside and Fife, among those who received at least one prescription in 2016 
A total 1,684 patients were prescribed both gabapentin and pregabalin in Tayside and 




8).  Overall, only two patients (0.1%) were under 18 years old and most patients 
(44.1%) were in the age group, 41-60 years old; 1,091 patients (64.8%) were female; 
and 978 patients (58.1%) were resident in Tayside (table 8).  The range of the 
proportion of patients amongst the five SIMD categories was 11.3%~23.0% (table 8).  
There were 699 patients (41.5%) resident in other urban areas and 39 patients (2.3%) 
resident in remote small town.  These patients received 6,413 prescriptions of 
gabapentin and 7,373 prescriptions of pregabalin totally in 2015, and average number 
of pregabalin prescriptions per patient received were more than that of gabapentin 
prescriptions (4.38 and 3.81prescriptions) (Table 8). 
In 2016, there were 1,777 patients prescribed both gabapentin and pregabalin in Tayside 
and Fife (Table 8).  The average age was 57.83 (SD 15.75) (Table 8).  Overall, only 
two patients (0.1%) were under 18 years old and most patients (45.2%) were in the age 
group, 41-60 years old; 1,142 patients (64.3%) were female; and 924 patients (52.0%) 
were resident in Tayside (Table 8).  The range of the proportion of patients amongst 
the five SIMD categories was 11.2%~25.4% (Table 8).  There were 775 patients 
(43.6%) resident in other urban areas and 15 patients (0.8 %) resident in remote small 
town.  These patients received 6,837 prescriptions of gabapentin and 7,559 
prescriptions of pregabalin in total in 2016, and the average number of pregabalin 
prescriptions received per patient was more than that of gabapentin prescriptions (4.25 




Table 8. The demographic characteristics of patients who received both gabapentin and pregabalin in 
Tayside and Fife in 2015 and 2016 
 2015 (N=1,684) 2016 (N=1,777) 
Age (mean, SD) 56.61(15.66) 57.83 (15.75) 
Age group   
 0-17 2 (0.1%) 2 (0.1%) 
 18-40 266 (15.8%) 341 (19.2%) 
 41-60 743 (44.1%) 803 (45.2%) 
 61-80 561 (33.3%) 528 (29.7%) 
 80+ 112 (6.7%) 103 (5.8%) 
Gender    
 Female 1,091 (64.8%) 1,142 (64.3%) 
 Male 593 (35.2%) 635 (35.7%) 
Health board   
 Tayside 978 (58.1%) 924 (52.0%) 
 Fife 706 (41.9%) 853 (48.0%) 
SIMD   
 Missing 71 (4.2%) 81 (4.6%) 
 SIMD1 387 (23.0%) 452 (25.4%) 
 SIMD2 330 (19.6%) 394 (22.2%) 
 SIMD3 338 (20.1%) 314 (17.7%) 
 SIMD4 367 (21.8%) 337 (19.0%) 
 SIMD5 191 (11.3%) 199 (11.2%) 
Rurality classification in 
Scotland 
  
 Missing 71 (4.1%) 81 (4.6%) 
 Large urban  402 (23.9%) 431 (24.3%) 
 Other urban 699 (41.5%) 775 (43.6%) 
 Accessible small town 172 (10.2%) 201 (11.3%) 
 Remote small town 39 (2.3%) 15 (0.8%) 
 Accessible rural 261 (15.5%) 242 (13.6%) 
 Remote rural 40 (2.4%) 32 (1.8%) 
Number of prescriptions group gabapentin Pregabalin gabapentin pregabalin 
    Sum  6,413 7,373 6,837 7,559 
 Range 1-29 1-25 1-31 1-28 
 Mean 3.81 4.38 3.85 4.25 
 Mode 1 1 1 1 




Overall, among the 36,800 patients who were prescribed a gabapentinoid, at least once 
in 2015 and 2016, 501 patients had at least one cancer episode.  The mean age was 
68.3; with 1.3% of female patients and 1.5% of male patients having cancer (Table 9).  
Patients of older age are more likely to have cancer (Table 9).   
Table 9. The characteristics for patients with cancer episodes among patients who were prescribed a 
gabapentinoid at least once in Tayside and Fife in 2015 and 2016 
 No cancer (n=36299) At least one episode 
(n=501) 
Age (mean, SD) 58.05 (16.1) 68.34 (14.6) 
Age group   
 0-17 45 (97.8%) 1 (2.2%) 
 18-40 5,445 (99.5%) 26 (0.5%) 
 41-60 14,799 (99.3%) 105 (0.7%) 
 61-80 12,781 (98.0%) 261 (2.0%) 
 80+ 3,229 (96.8%) 108 (3.2%) 
Gender    
 Male  13,602 (98.5%) 202 (1.5%) 
 Female  22,697 (98.7%) 288 (1.3%) 
 
Among the 36,800 patients, 2,357 patients died during 2015 and 2016 the average age 
was found to be 71.  The proportion of dead patients in the age group 80+ was the 
largest (19.7%) (Table 10).  
Table 10. The basic characteristics for patients who died among patients who were prescribed at least one 
gabapentinoid in Tayside and Fife in 2015 and 2016 
 Dead (n=2,357) Alive (n=34,443) 
Age (mean, SD) 71.0 (14.7) 57.3 (15.9) 
Age group   
 0-17 2 (4.3%) 44 (95.7%) 
 18-40 79 (1.4%) 5,392 (98.6%) 
 41-60 447 (3.0%) 14,457 (97.0%) 
 61-80 1,172 (9.0%) 11,870 (91.0%) 
 80+ 657 (19.7%) 2,680 (80.3%) 
Gender    
 Male  1,121 (8.1%) 12,689 (91.9%) 






The underlying cause of death was categorized into six groups.  The most deaths were 
caused by neoplasms (1,068), which was reported as 45.3% (Table 11).  Only 93 
deaths were caused by disease of digestive system (Table 11). 
Table 11. The underlying cause of death in patients prescribed gabapentinoids in 2015 and 2016 in 
Tayside and Fife. 
Cause of death Frequency Percent 
All circulatory system 444 18.8% 
 Acute myocardial infarction 98 22.1% 
 Ischaemic heart disease including angina 115 25.9% 
 Cerebrovascular disease 31 7.0% 
 Other circulatory system 200 45.0% 
All neoplasms 1,068 45.3% 
 Neoplasms of the digestive organs 238 22.2% 
 Neoplasms of the respiratory and intrathoracic organs 304 28.4% 
 Other neoplasms 526 49.3% 
Disease of respiratory system 267 11.3% 
 Pneumonia 63 23.6% 
 Chronic lower respiratory disease 133 49.8% 
 Other  71 26.6% 
Disease of digestive system 93 4.0% 
Disease of the nervous system 103 4.4% 
All other causes 382 16.2% 
Total 2,357 100% 
 
Overall, among the total 36,800 patients, there were 10,629 (28.9%) patients using 
hospital admission services and 9,156 (24.9%) patients using A&E services.  For 
hospital services, the average counts of attendance per patient was 2.96 (±3.4) and the 
range was 1 to 66 (Table 12-a).  The mean of average length each patient stayed was 
3.2 days and the length of stay ranged from 0 to 290 days (Table 12-b).  For A&E 
services the mean of counts of attendance per patient was 1.69 (±2.0) and the range was 



















counts of admission 10,629 1 66 31,507 2.96 3.4 
counts of A&E 9,156 1 83 15,484 1.69 2.0 
 
Table 12-b. The descriptive analysis for length of stay at hospital admission with 10,629 patients 
 Minimum Maximum Mean SD 
average length of stay per 
patient 
0.0 201.0 3.2 6.6 
min of length per patient 0 201 1.3 4.3 
max of length per patient 0 290 7.0 15.9 
3.3.3. Logistic regression model 
The association between demographic factors and prescription of pregabalin rather than 
gabapentin in 2015 and 2016 was examined by logistic regression modelling.   
In 2015, there were 24,953 patients prescribed only gabapentin or only pregabalin, only 
23,986 patients with complete information; 967 patients missing information on SIMD 
and rurality factors.  Thus, the population the logistic regression model analysed was 
23,986 patients who were prescribed only gabapentin or only pregabalin, excluding 
patients who were prescribed both gabapentin and pregabalin.  The positive outcome 
was pregabalin prescribed and the negative one was gabapentin prescribed.  Patients 
resident in Fife were more likely to be prescribed gabapentin other than pregabalin than 
patients in Tayside (P <0.001) (Table 13).  Patients resident in the most deprived areas 
were more likely to be prescribed gabapentin rather than pregabalin than patients 
resident in more affluent areas (P<0.001) (Table 13).  Patients resident in accessible 
small towns and accessible rural area were more likely to prescribed pregabalin rather 
than gabapentin, compared with patients living in other urban area (both P = 0.01) 
(Table 13).  Patients aged 61-80 and 80+ were more likely to be prescribed gabapentin 




Table 13. The association between demographic factors and prescription of pregabalin rather than 
gabapentin in 2015 among patients who only received gabapentin or pregabalin. 
 
Estimated 
effect size S.E. P-value OR 
95% C.I.for OR 
Lower Upper 
Age        
 0-17 -0.98 0.63 0.12   0.38 0.11 1.29 
 18-40 0.03 0.05 0.49 1.03 0.94 1.13 
 61-80 -0.19 0.03 <0.01 0.86 0.77 0.88 
 80+ -0.24 0.05 <0.01 0.79 0.71 0.86 
 41-60 Reference category 
Gender        
 Male  -0.06 0.03 0.06 0.94 0.89 1.00 
 Female  Reference category 
Health board       
 Fife  -0.84 0.04 <0.01 0.43 0.40 0.47 
 Tayside  Reference category 
SIMD       
 SIMD2 0.18 0.05 <0.01 1.19 1.09 1.30 
 SIMD3 0.25 0.05 <0.01 1.29 1.17 1.42 
 SIMD4 0.26 0.05 <0.01 1.29 1.18 1.42 
 SIMD5 0.26 0.05 <0.01 1.30 1.17 1.44 
 SIMD1 Reference category 
Rurality        
 Large urban 0.07 0.04 0.09 1.08 0.99 1.17 
 Accessible small towns 0.14 0.05 0.01 1.15 1.04 1.27 
 Remote small towns 0.19 0.11 0.07 1.21 0.98 1.49 
 Accessible rural area 0.13 0.05 0.01 1.13 1.04 1.25 
 Remote rural area -0.14 0.11 0.23 0.87 0.70 1.09 







In 2016, there were 27,345 patients prescribed only gabapentin or only pregabalin, only 
26,225 patients with complete information; 1,120 patients missing information on 
SIMD and rurality factors.  Thus, the population the logistic regression model 
analysed was 26,225 patients were prescribed only gabapentin or only pregabalin, 
excluding patients who were prescribed both gabapentin and pregabalin.  The positive 
outcome was pregabalin prescribed.  Patients resident in Fife were more likely to 
prescribe gabapentin other than pregabalin than patients in Tayside (P <0.001) (Table 
14).  Patients resident in the most deprived areas were more likely to be prescribed 
gabapentin rather than pregabalin than patients in other socioeconomic classes 
(P<0.001) (Table 14).  Patients resident in accessible small towns and accessible rural 
area were more likely to be prescribed pregabalin rather than gabapentin than patients 
in other urban area (P<0.001 and =0.01 respectively) (Table 14).  Compared with 
patients aged 41-60, patients aged 18-40 were 41.2% more likely to be prescribed 
pregabalin rather than gabapentin (P<0.001), while patients aged 61-80 were 6% less 





Table 14. The association between demographic factors and prescription of pregabalin rather than 
gabapentin in 2016 among patients who only received gabapentin or pregabalin. 
 Estimated effect size S.E. P-value OR 95% CI for OR 
     Lower Upper 
Age        
 0-17 0.59 0.45 0.19 1.80 0.75 4.34 
 18-40 0.35 0.04 <0.01 1.41 1.30 1.53 
 61-80 -0.06 0.03 0.04 0.94 0.89 1.00 
 80+ -0.02 0.05 0.66 0.98 0.89 1.08 
 41-60 Reference category 
Gender        
 Male  0.02 0.03 0.48 1.02 0.97 1.08 
 Female  Reference category 
Health board      
 Fife  -0.45 0.03 <0.01 0.64 0.60 0.68 
 Tayside  Reference category 
SIMD       
 SIMD2 0.20 0.04 <0.01 1.23 1.14 1.32 
 SIMD3 0.33 0.04 <0.01 1.40 1.28 1.52 
 SIMD4 0.37 0.04 <0.01 1.44 1.32 1.57 
 SIMD5 0.52 0.05 <0.01 1.68 1.54 1.85 
 SIMD1 Reference category 
Rurality        
 Large urban 0.05 0.04 0.21 1.05 0.97 1.14 
 Accessible small towns 0.15 0.04 <0.01 1.17 1.07 1.27 
 Remote small towns 0.19 0.11 0.08 1.20 0.98 1.48 
 Accessible rural area 0.11 0.04 0.01 1.12 1.03 1.22 
 Remote rural area 0.12 0.11 0.26 1.13 0.91 1.40 
 Other urban Reference category 
 
3.3.4. Poisson regression model 
The associations between the demographic factors and the number of gabapentinoids 
prescribed in 2015 and 2016 were evaluated by using the Poisson regression model 
(Tables 15-18).  Gabapentin and pregabalin were examined separately. 
The study population for the first Poisson model was those patients who were 
prescribed gabapentin at least once in 2015.  The results showed that male patients 




patients were (P<0.001).  Patients living in Tayside and the most deprived areas 
(SIMD1) were more likely to receive more gabapentin prescriptions compared with 
patients in Fife and more affluent areas (both P-value<0.001).  As age increased, 
patients were more likely to receive more gabapentin prescriptions in 2015 (P-
value<0.001).  Compared with other urban areas, patients in large urban areas were 
likely to receive fewer less gabapentin prescriptions (P=0.01).  There was no 






Table 15. The first Poisson model- association between demographic factors and the number of 





95% Wald Confidence Interval  
Lower Upper p-value 
(Intercept) 1.87 0.02 1.84 1.90 <0.01 
Gender       
 Male  0.02 0.01 0.01 0.04 <0.01 
 Female  Reference category 
Health board      
 Fife  -0.09 0.01 -0.11 -0.07 <0.01 
 Tayside  Reference category 
SIMD      
 SIMD2 -0.09 0.01 -0.11 -0.07 <0.01 
 SIMD3 -0.15 0.01 -0.17 -0.13 <0.01 
 SIMD4 -0.21 0.01 -0.23 -0.19 <0.01 
 SIMD5 -0.29 0.01 -0.31 -0.27 <0.01 
 SIMD1 Reference category 
Rurality       
 Large urban -0.03 0.01 -0.05 -0.01 0.01 
 Accessible small 
towns 
-0.01 0.01 -0.03 0.01 0.54 
 Remote small towns 0.01 0.03 -0.04 0.06 0.57 
 Accessible rural area 0.01 0.01 -0.01 0.03 0.43 
 Remote rural area -0.03 0.03 -0.08 0.02 0.23 
 Other urban Reference category 
Age  0.01 0.01 0.01 0.01 <0.01 
The study population for the second Poisson model was the patients who received at 
least one gabapentin prescription in 2016.  Older age was related to more gabapentin 
prescriptions (P<0.001).  Patients resident in Tayside and the most deprived areas 
(SIMD1) were more likely to be prescribed more gabapentin prescriptions in 2016 
compared with patients in Fife and more affluent areas (both P<0.001), while patients 
living in large urban and accessible rural area were more likely to receive fewer 
gabapentin prescriptions than those in other urban areas in 2016 (P<0.001).  However, 
after controlling other demographic variables, gender was not significantly related to 






Table 16. The second Poisson model- association between the demographic factors and the number of 





95% Wald Confidence Interval 
P-value 
Lower Upper 
(Intercept) 1.89 0.01 1.86 1.92 <0.01 
Gender       
 Male  0.01 0.01 -0.01 0.02 0.07 
 Female Reference category 
Health board      
 Fife  -0.09 0.01 -0.11 -0.07 <0.01 
 Tayside  Reference category 
SIMD      
 SIMD2 -0.07 0.01 -0.08 -0.05 <0.01 
 SIMD3 -0.15 0.01 -0.17 -0.13 <0.01 
 SIMD4 -0.22 0.01 -0.24 -0.20 <0.01 
 SIMD5 -0.29 0.01 -0.30 -0.26 <0.01 
 SIMD1 Reference category 
Rurality       
 Large urban -0.06 0.01 -0.07 -0.03 <0.01 
 Accessible small 
towns 
-0.01 0.01 -0.03 0.01 0.16 
 Remote small towns -0.01 0.02 -0.06 0.03 0.55 
 Accessible rural area -0.03 0.01 -0.04 -0.01 0.01 
 Remote rural area -0.03 0.02 -0.07 0.02 0.30 
 Other urban Reference category 
Age 0.01 0.01 0.01 0.01 <0.01 
The study population for the third Poisson model was the patients who had at least one 
pregabalin prescription in 2016.  Older patients received less number of pregabalin 
prescriptions being issued (P<0.001).  Tayside and SIMD1 residence were factors 
associated with a higher number of pregabalin prescriptions (both P<0.001), while there 
was no significant difference between those in the SIMD2 quintile and SIMD1 quintile.  
Additionally, there were no significant associations between gender, rurality and the 







Table 17. The third Poisson model- association between the demographic factors and the number of 





95% Wald Confidence Interval 
P-value 
Lower Upper 
(Intercept) 2.14 0.02 2.10 2.18 <0.01 
Gender       
 Male  0.01 0.01 -0.01 0.03 0.06 
 Female  Reference category 
Health board      
 Fife -0.10 0.01 -0.12 -0.08 <0.01 
 Tayside Reference category 
SIMD      
 SIMD2 0.01 0.01 -0.02 0.02 0.75 
 SIMD3 -0.07 0.01 -0.09 -0.04 <0.01 
 SIMD4 -0.09 0.01 -0.12 -0.06 <0.01 
 SIMD5 -0.16 0.01 -0.19 -0.13 <0.01 
 SIMD1 Reference category 
Rurality       
 Large urban -0.01 0.01 -0.03 0.01 0.25 
 Accessible small 
towns 
-0.02 0.01 -0.05 0.01 0.09 
 Remote small towns 0.04 0.02 -0.01 0.09 0.09 
 Accessible rural area 0.01 0.01 -0.02 0.02 0.93 
 Remote rural area 0.03 0.03 -0.02 0.09 0.22 
 Other urban Reference category 
Age -0.01 <0.01 -0.01 -0.01 <0.001 
 
 
The study population of the fourth Poisson model was patients who had at least one 
pregabalin prescription in 2016.  Being resident in Tayside or in the most deprived 
areas would increase the likelihood of receiving more pregabalin prescriptions (both 
P<0.001), while there was no significant difference between SIMD2 and SIMD1 
quintiles.  Older age would decrease the likelihood of receiving more pregabalin 
prescriptions (P<0.001).  Compared with patients living in other urban areas, patients 
living in remote small towns were more likely to receive more pregabalin prescriptions 
(P=0.01).  Gender was not significantly related to the number of pregabalin 





Table 18. The fourth Poisson model- association between the demographic factors and the number of 
pregabalin prescribed in 2016 among patients who prescribed pregabalin at least once in 2016 
Variables 
Estimated 
effect size SE 
95% Wald Confidence Interval 
P-value Lower Upper 
(Intercept) 2.17 0.01 2.14 2.21 <0.01 
Gender       
 Male  0.01 0.01 -0.01 0.03 0.14 
 Female Reference category 
Health board      
 Fife  -0.10 0.01 -0.12 -0.09 <0.01 
 Tayside Reference category 
SIMD      
 SIMD2 -0.01 0.01 -0.04 0.01 0.13 
 SIMD3 -0.08 0.01 -0.11 -0.06 <0.01 
 SIMD4 -0.11 0.01 -0.14 -0.09 <0.01 
 SIMD5 -0.19 0.01 -0.22 -0.16 <0.01 
 SIMD1 Reference category 
Rurality       
 Large urban -0.02 0.011 -0.04 <0.01 0.05 
 Accessible small towns -0.01 0.013 -0.03 0.01 0.61 
 Remote small towns 0.08 0.024 0.03 0.13 0.01 
 Accessible rural area -0.01 0.012 -0.04 0.01 0.15 
 Remote rural area 0.04 0.028 -0.01 0.10 0.11 
 Other urban Reference category 
Age >-0.01 <0.01 >-0.01 >-0.01 <0.01 
3.3.5. Age standardised mortality 
The age standardised mortality risk for overall deaths in the population prescribed 
gabapentinoids was 3.93 (CI 3.82-4.05) times higher than that in the Scottish general 
population during 2015 & 2016 combined (Table 19).  The age standardised death rate 
risks for circulatory deaths and respiratory deaths in our study population were 2.10 
and 2.56 times that of the Scottish population (Table 19).  All the findings were 






Table 19. The comparison of age standardised mortality (per 100,000 persons) between Scotland and 
those prescribed a gabapentinoid at least once in Tayside and Fife in 2015 and 2016 




death rate -Scotland 
population 




Overall  4,550.85 1,156.85 3.93 (3.82-4.05) <0.001 
Circulatory  664.15 315.8 2.1 (1.95-2.27) <0.001 
Respiratory  394.06 154.15 2.56 (2.32-2.81) <0.001 
 
3.4. Discussion 
This study is the first study to quantify the trends of gabapentin or pregabalin 
prescribing in Tayside, Fife and Scotland.  This study used the number of gabapentin 
or pregabalin prescriptions and the number of patients who were prescribed at least one 
gabapentin or pregabalin.  The prevalence of prescriptions and number of patients 
were also calculated to quantify and compare the gabapentin or pregabalin prescribing 
rates between Tayside, Fife and Scotland.  It was found that the number of gabapentin 
prescriptions increased in Fife from 2010 to 2016 (around a 3-fold increase from 2010 
to 2016); in Tayside, the number of gabapentin prescriptions increased from 2006 to 
2010 and then slightly decreased in 2010/11 and then increased gradually from 2011 to 
2016 (around 3.5-fold increase in 2016 compared with 2006).  The number of patients 
who were prescribed gabapentin at least once increased in Tayside from 2006 to 2016 
(a 4-fold increase) and Fife from 2010 to 2016 (a 2.65-fold increase).  In Fife, the 
prevalence of gabapentin prescribing increased rapidly from 2010 to 2016; in Tayside 
and Scotland, there were a slight decrease in 2011 before rising.  The prevalence of 
gabapentin prescribing in Scotland was a little higher than in Tayside every year from 
2006 to 2016, while the prevalence in Fife exceeded that in Scotland in 2013.  The 
number of patients who were prescribed gabapentin at least once increased in Tayside 
and Fife and it was higher in Fife than in Tayside after 2012.  The number of 




Scotland (a 16-fold increase) from 2006 to 2016 and it increased gradually in Fife from 
2010 to 2016 (around a two-fold increase).  The number of patients who were 
prescribed pregabalin at least once increased in Tayside from 2006 to 2016 (a 15-fold 
increase), while it slightly decreased in Fife in 2012 before rising.  The prevalence of 
pregabalin prescribing was higher in Tayside than in Fife and Scotland from 2011.  
The number of patients who were prescribed pregabalin at least once was higher in 
Tayside than in Fife from 2011.  From the NHS Digital prescribing cost analysis 
website, it was found that in England, the number of gabapentin prescription items 
increased from 2010 to 2015, with 2,435,500 prescriptions (2010), 2,905,800 
prescriptions (2011), 3,531,900 prescriptions (2012), 4,212,300 prescriptions (2013), 
4,978,900 prescriptions in (2014), and 5,723,000 prescriptions in (2015) (59–64).  The 
number of pregabalin prescriptions increased by 182% in England from 2010 to 2015, 
with 1,698,300 prescriptions (2010), 2,205,400 prescriptions (2011), 2,730,700 
prescriptions (2012), 3,349,800 prescriptions (2013), 4,086,400 prescriptions (2014), 
and 4,801,600 prescriptions (2015) (59–64).  The numbers of gabapentin prescriptions 
and pregabalin prescriptions were much higher in England than that in Scotland every 
year from 2010 to 2015.  That is mainly because the population is 10 times higher in 
England than that in Scotland (65). 
The prescribing dataset in this study is from GP prescribing records and is provided by 
HIC.  It is a community-dispensed prescription dataset, so most prescriptions were 
written by GPs and only a small number of prescriptions were written by nurses, 
pharmacists and dentists.  The dataset also includes prescriptions written in hospital 
but dispensed in the community but excludes the prescriptions within hospitals.  It 
also excludes the prescriptions in prison and private prescriptions.  Thus, the number 
of gabapentin and pregabalin prescriptions in Tayside and Fife may be a little 
underestimated, but it was comparable with Scottish national data which was 
summarised by ISD from community-dispensed dataset, and the number excluded from 




The main reasons for choosing data from Tayside and Fife were practical.  The way 
for us to access the data was through HIC from which complete, high quality 
prescribing data relating to each patient in Tayside and Fife was available.  Using the 
CHI number, we could also utilise HIC collected data in relation to cancer, death and 
use of hospital services.  This level of individual data and linkage would not have been 
practical further afield, including elsewhere in Scotland.  Thus, Tayside and Fife were 
the ideal setting to identify the possible factors related to gabapentinoids prescribing 
and its outcomes, in order to improve the safety of gabapentinoids usage.   
Our study began in 2017, so we chose the latest available full year of data which was 
in 2016.  This epidemiology study aimed to calculate the gabapentinoids use over 10 
years, to illustrate the changes in rates in these two health boards.  However, 
prescribing data from Fife only became available to HIC from 2010 and so only Tayside 
could provide data for the full 10-year period.  For the investigation of health 
outcomes and use of health service, this study only used data in 2015 and 2016, because 
cancer, death, hospital admission, A&E and outpatient admission datasets provided by 
HIC were only provided for 2015 or 2016.   
In Scotland, gabapentin and pregabalin are both licensed as treatment for peripheral 
neuropathic pain and focal seizures, while pregabalin is also licensed for central 
neuropathic pain and general anxiety disorder (GAD) (25,67).  Thus, the overall 
trends of gabapentinoids prescribing may suggest there was a rise in the prevalence of 
neuropathic pain and epilepsy with focal seizures in Tayside, Fife and Scotland.  
However, other studies also found gabapentinoids prescribing for unlicensed 
indications and these indications were for other types of pain, including migraine, 
sciatica, arthritis; methadone reduction; chest pain (30).  Thus, if the growth of 
gabapentin and pregabalin prescriptions could not be totally explained by an increasing 
prevalence of neuropathic pain, epilepsy and GAD, it could also be due to a switch to 
these drugs from other drugs previously used to treat neuropathic pain or a greater 




This would be consistent with recent evidence which showed there was a rise in 
gabapentinoids misuse and abuse (25,69,70).  To identify the reason why there was a 
rapid increase in gabapentinoids prescribing, a further study on the trends of patients 
with neuropathic pain, epilepsy and GAD should be investigated and the size of 
gabapentinoids misuse in Tayside and Fife also should be identified. 
For the data-linkage, there were 36,800 patients prescribed a gabapentinoid at least once 
in Tayside and Fife in 2015 and 2016.  The distributions of number of gabapentin or 
pregabalin prescriptions for each patient each year were positively skewed, and they 
were all similar in male and female.  The frequency of one prescription of gabapentin 
or pregabalin receiving in one year was the greatest whether they were female or male 
patients in 2015 and 2016 (figure 14), but more patients received more than one 
prescription and the ranges in the number of gabapentin and pregabalin prescriptions 
were 1 to 36 and 1 to 52 in 2015 and 2016.  The ranges might simply represent more 
prescriptions with fewer tablets each time in a positive aspect, which means patients 
are at less risk of overdose, while negatively, drug overdose and repeat prescription 
availability may also need to be recognised.  These findings suggest that a further 
study on whether overdose and repeat prescriptions were received by patients every 
year is needed.  Even though there is a proposal to reclassify gabapentin and 
pregabalin as C Controlled Drugs which means a repeat prescription would not be 
established (71), the process still needs more evidence.  Thus, the large number of 
prescriptions per patient per year in Tayside and Fife and the rapid increase of 
gabapentinoids prescriptions suggest that further study on repeat prescriptions available 
could provide some evidence for the proposal above.  It was also found there were 
patients prescribed both gabapentin and pregabalin in 2015 and 2016, which means 
some patients switched between gabapentin and pregabalin (72).  Therefore, it also 
could be hypothesized that part of the changes in gabapentinoids prescribing rates may 




According to the search of systematic reviews, there were no studies investigating the 
association between the gabapentin or pregabalin prescribing and demographic factors, 
so this study is the first study to identify the potential factors which may influence the 
gabapentin or pregabalin prescribing, using two different statistics model to investigate 
the associations, logistic regression model and Poisson regression model.   
Poisson modelling was used to identify whether there was association between 
demographic factors and the number of gabapentin or pregabalin prescriptions received.  
It was found there was a significant association between Health Board, deprivation, age 
and rurality and the number of gabapentin prescriptions received.  Patients resident in 
Tayside and SIMD1 were more likely to receive a larger number of gabapentin and 
pregabalin prescriptions per year in 2015 and 2016.  Similar associations were found 
in a study of the epidemiology of opioids prescribing in Scotland (73).  As the age 
increased, the average number of gabapentin prescriptions per patient was larger, while 
the number of pregabalin prescriptions per patient was smaller.  These findings were 
consistent with the results from the logistic regression model in this study.  Patients in 
younger age groups were more likely to be prescribed pregabalin rather than gabapentin.  
Patients resident in Fife and SIMD1 were more likely to be prescribed gabapentin rather 
than pregabalin.  The reasons for these differences are probably partly due to the 
different prevalence of neuropathic pain, epilepsy and GAD in different age groups and 
different socioeconomic classes.  Because gabapentin and pregabalin are both licensed 
for focal seizures and peripheral neuropathic pain (67), another reason may lie in the 
choice of gabapentin or pregabalin by GPs or the requests of patients.  Gabapentin is 
recommended as the 1st or 2nd line for neuropathic pain and pregabalin should only be 
used if gabapentin is not tolerated or ineffective (11).  There is a report about the 
concerns on the choice of gabapentin and pregabalin in UK (74).  This report (74) 
illustrated that gabapentin and pregabalin both have a high efficacy in treatment of 
peripheral neuropathic pain with a number needed to treat (NNT) of 4.2 for pregabalin 
and NNT of 5.1 for gabapentin to achieve a 50% pain relief and with similar side-effects, 




gabapentin is much cheaper than pregabalin and the price comes from the prescribing 
budget, so there is a choice for NHS that with the same level of investment, is it better 
to treat more patients with the cheaper one but seemingly less effective or to treat fewer 
patients with the more expensive one but seemingly more effective and simple (74).  
These findings may raise a hypothesis that age, and socioeconomic circumstances will 
influence the number of gabapentin or pregabalin prescriptions and the choice of 
gabapentin and pregabalin for the same disease. 
The age standardised mortality among the population prescribing gabapentinoids was 
3.93 times higher than that among the Scottish general population, which suggested 
gabapentinoids prescribing might be associated with higher mortality.  This finding is 
consistent with recent published evidence (25,75,76).  However, it does not take 
account of the reasons for prescribing, and adverse selection which means that those 
who are prescribed a gabapentin are more likely to be sicker than the average person in 
the population.  This preliminary finding needs further investigation, including 
comparison between similar populations (those with treatment for other chronic 
conditions) and those with neuropathic pain who are not prescribed gabapentinoids.    
This study illustrated the prescribing trends of gabapentin and pregabalin and the 
distribution of gabapentinoids prescribing among demographic factors.  There are 
some strengths in this study.  Firstly, the datasets were cleaned and managed well 
before they underwent the further analysis.  The GP gabapentinoids prescribing 
datasets in 2015 and 2016 were merged into one dataset (Dataset 2) with the form, 
single record for each patient, including the number of gabapentin or pregabalin 
prescriptions in 2015 and 2016 respectively and there were 36,800 patients included.  
The duplications and 214 cases missing Pro-CHI were removed.  The demographic 
file, A&E dataset, hospital admission file, cancer registration file, death file and 
outpatient admission file were linked with Dataset 2 by matching the Pro-CHI of 
patients, the unique identifier.  This linking is only possible in Scotland where each 




2 determined the number of patients and the other datasets were only used to add the 
variables not influencing the final size.  The data linkage added more variables into 
the dataset and made the dataset more comprehensive for data analysis.  Secondly, the 
age standardised mortality among the population prescribed gabapentinoids was 
compared with the Scottish general population, which implied an association between 
gabapentinoids prescribing and death.  Thirdly, this study summarised the pattern of 
health service use among population with gabapentinoids prescribing, which 
contributed to a further analysis of the associations between gabapentinoids prescribing 
and health service use after adjusting for confounders.  Additionally, this study 
summarised the main causes of death among patients with gabapentinoids prescribing, 
which could be used to generate hypotheses about the associations between underlying 
death cause and gabapentinoids prescribing to understand the potential health problem 
caused by gabapentinoids.  Another strength of this study is that it used two kinds of 
statistics model, logistic regression model and Poisson model, to identify the 
associations between gabapentinoids prescribing and demographic factors.  The two 
kinds of model have different functions and were mutually complementary in this study.  
The logistic regression model was to identify how the factors influenced the likelihood 
of being prescribed pregabalin rather than gabapentin and the Poisson model was to 
identify which factors increased the likelihood of receiving a higher number of 
gabapentin or pregabalin prescriptions.  These findings could help us propose specific 
hypotheses about the risk factors and reasons related gabapentinoids prescribing.  
However, this study still has some limitations.  First, the most important limitation is 
that this study failed to compare health outcomes (hospital attendance, outpatient 
attendance, A&E attendance, cancer, mortality) or demographic factors between people 
who had received a gabapentinoid and those who had not, which would have been the 
ideal analysis to test the associations.  However, due to the dataset we had, we did not 
have the data on people who had not received a gabapentinoid.  Thus, this study could 
only compare these factors between those who had received gabapentin and those had 




missing Pro-CHI were removed before dataset linkage, because these non-completed 
cases could not be matched with other variables without this unique identifier.  Thus, 
the information from these 214 patients was not analysed and this might bias the 
distribution among demographic factors.  However, this was a very small proportion 
of the total number who received a gabapentinoid prescription.  Thirdly, the 
demographic file provided by HIC included 22 variables, but some of them conveyed 
the same information, such as SIMD with five classifications and SIMD with ten 
classifications, date of birth and age, rurality with different classifications.  The 
demographic factors chosen in this study only included age, gender, SIMD with five 
classifications, rurality with six classifications and Health Board.   Even though this 
study examined the associations with the five demographic factors and gabapentinoids 
prescribing, there are still many other potential confounders not adjusted for, such as 
education background, type of work, type of family, marriage status, alcohol, smoking 
status and disease history which are related to neuropathic pain, epilepsy and GAD (77–
79).  Then, this study failed to examine the association of gabapentinoids prescribing 
with health service use and cancer, because there were many other factors related to 
health service use and cancer episodes, and these potential confounders, such as disease 
history, diagnosed main health problem, were not provided by the original datasets.  
The original dataset did not provide the reasons for gabapentin or pregabalin 
prescriptions, so we could not find the pattern of reasons why gabapentin and 
pregabalin were prescribed.  Thus, we could not find the reasons to explain the trends 
and associations with demographic factors, but only generated hypotheses.  Finally, 
the original prescribing datasets provided all gabapentin and pregabalin prescriptions 
from 2006 to 2016.  However, this study did not analyse all patients prescribed 
pregabalin from 2006, but only prescribing data in 2015 and 2016 to identify the 
associations.  The associations may vary in different years.  
This study is an epidemiological study to quantify the trends of gabapentin and 
pregabalin prescribing and describe the distribution pattern of prescriptions among 




pregabalin prescribing and generate hypotheses about the reasons.  Additionally, this 
study will contribute to a planned programme studying gabapentinoids prescribing in 
Scotland, to investigate the reasons, to quantify the indications of gabapentin and 
pregabalin prescribed, to find the details about gabapentinoids misuse and abuse in 
Scotland and determine associated health problems.  This is likely to inform policy 
and practice relating to gabapentinoids prescribing in Scotland and further afield. 
 
3.5. Conclusion 
The overall trends of gabapentin and pregabalin prescribing in Tayside and Scotland 
from 2006 to 2016 and Fife from 2010 to 2016 are rising.  It was found that age, 
deprivation, Health Board area of residence and some levels of rurality were associated 
with gabapentin and pregabalin prescribing, and also associated with the number of 
gabapentin and pregabalin prescriptions received.  The age standardised mortality 
among those receiving at least one gabapentinoid prescription was higher than in the 
Scottish general population.  Further study on the reasons, indications, determinants, 
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Appendix 2. The Preferred Reporting Items for Systematic Reviews and Meta-
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Appendix 3. The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) checklist 
  
Section and Item  
Item 




Title and Abstract   1  (a) Indicate the study’s design with a commonly used 
term in the title or the abstract   
  
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found    
  
Introduction    
Background/Rationale  2  Explain the scientific background and rationale for the 
investigation being reported    
  
Objectives  3  State specific objectives, including any prespecified 
hypotheses   
  
Methods    
Study Design  4  Present key elements of study design early in the paper     
Setting  5  Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-up, 
and data collection   
  
Participants  6  (a) Cohort study—Give the eligibility criteria, and the 
sources and methods of selection of participants. 
Describe methods of follow-up   
Case-control study—Give the eligibility criteria, and 
the sources and methods of case ascertainment and 
control selection. Give the rationale for the choice of 
cases and controls   
Cross-sectional study—Give the eligibility criteria, and 
the sources and methods of selection of participants  
  
(b) Cohort study—For matched studies, give matching 
criteria and number of exposed and unexposed   
Case-control study—For matched studies, give 
matching criteria and the number of controls per case    
  
Variables  7  Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 







Item  Item 




Data Sources/  
Measurement  
8*   For each variable of interest, give sources of data and details 
of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one 
group    
  
Bias  9  Describe any efforts to address potential sources of bias      
Study Size  10  Explain how the study size was arrived at      
Quantitative 
Variables  
11  Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were chosen 




12  (a) Describe all statistical methods, including those used to 
control for confounding    
  
(b) Describe any methods used to examine subgroups and 
interactions    
  
(c) Explain how missing data were addressed     
(d) Cohort study—If applicable, explain how loss to follow-up 
was addressed   
Case-control study—If applicable, explain how matching of 
cases and controls was addressed    
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy    
  
(e) Describe any sensitivity analyses     







(a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, 
and analysed  
  
(b) Give reasons for non-participation at each stage      









Item  Item 











(a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders     
  
(b) Indicate number of participants with missing data for each 
variable of interest    
  
(c) Cohort study—Summarise follow-up time (eg, average and 
total amount)     
  






Cohort study—Report numbers of outcome events or summary 
measures over time    
  
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure    
  
Cross-sectional study—Report numbers of outcome events or 
summary measures    
  






(a) Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and 
why they were included    
  
(b) Report category boundaries when continuous variables 
were categorized    
  
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period    
  
Other Analyses  17  Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses    
  
Discussion        
Key Results  18  Summarise key results with reference to study objectives      
Limitations  19  Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias    
  
Interpretation  20  Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 





Generalisability  21  Discuss the generalisability (external validity) of the study 




      
Section and 
Item  Item 




Funding  22  Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 
the present article is based    
  
  
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed 
and unexposed groups in cohort and cross-sectional studies.  
*Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 







Appendix 4. The data abstraction form of this systematic review 
data abstraction form 
title   
 
author   published year   country   
research question related 




study design   
setting location   
study period recruitment date   
exposure date   
 
follow-up    
data period   
 
data source   
study population target population   
clinical status   
 
cases exposure   
 
cohorts number of 
groups 
  
exposure   
gabapentin   pregabalin   both    
results 
study population sample size   
 
missing number   
age range   adults selected out or not   





prescribing rate   
 
prescribing trend   
 
main findings prescribing trend   
 





related health outcomes  
 
limitations 
sample size too small   
only prescribing portion   
no age information   








Appendix 5. The National Heart, Lung and Blood Institute (NHLBI) 





1. Was the research question or objective in this paper clearly 
stated? 
      
2. Was the study population clearly specified and defined?       
3. Was the participation rate of eligible persons at least 50%?       
4. Were all the subjects selected or recruited from the same or 
similar populations (including the same time period)? Were 
inclusion and exclusion criteria for being in the study 
prespecified and applied uniformly to all participants? 
      
5. Was a sample size justification, power description, or variance 
and effect estimates provided? 
      
6. For the analyses in this paper, were the exposure(s) of interest 
measured prior to the outcome(s) being measured? 
      
7. Was the timeframe sufficient so that one could reasonably 
expect to see an association between exposure and outcome if it 
existed? 
      
8. For exposures that can vary in amount or level, did the study 
examine different levels of the exposure as related to the 
outcome (e.g., categories of exposure, or exposure measured as 
continuous variable)? 
      
9. Were the exposure measures (independent variables) clearly 
defined, valid, reliable, and implemented consistently across all 
study participants? 









10. Was the exposure(s) assessed more than once over time?       
11. Were the outcome measures (dependent variables) clearly 
defined, valid, reliable, and implemented consistently across all 
study participants? 
      
12. Were the outcome assessors blinded to the exposure status of 
participants? 
      
13. Was loss to follow-up after baseline 20% or less?       
14. Were key potential confounding variables measured and 
adjusted statistically for their impact on the relationship between 
exposure(s) and outcome(s)? 
      
  
  
Quality Rating (Good, Fair, or Poor) 
Rater #1 initials: 
Rater #2 initials: 
Additional Comments (If POOR, please state why): 
*CD, cannot determine; NA, not applicable; NR, not reported 
Guidance for Assessing the Quality of Observational Cohort and Cross-Sectional Studies 
The guidance document below is organized by question number from the tool for quality assessment of 
observational cohort and cross-sectional studies. 
Question 1. Research question 
Did the authors describe their goal in conducting this research? Is it easy to understand what they were 
looking to find? This issue is important for any scientific paper of any type. Higher quality scientific 




Questions 2 and 3. Study population 
Did the authors describe the group of people from which the study participants were selected or 
recruited, using demographics, location, and time period? If you were to conduct this study again, 
would you know who to recruit, from where, and from what time period? Is the cohort population free 
of the outcomes of interest at the time they were recruited? 
An example would be men over 40 years old with type 2 diabetes who began seeking medical care at 
Phoenix Good Samaritan Hospital between January 1, 1990 and December 31, 1994. In this example, 
the population is clearly described as: (1) who (men over 40 years old with type 2 diabetes); (2) where 
(Phoenix Good Samaritan Hospital); and (3) when (between January 1, 1990 and December 31, 1994). 
Another example is women ages 34 to 59 years of age in 1980 who were in the nursing profession and 
had no known coronary disease, stroke, cancer, hypercholesterolemia, or diabetes, and were recruited 
from the 11 most populous States, with contact information obtained from State nursing boards. 
In cohort studies, it is crucial that the population at baseline is free of the outcome of interest. For 
example, the nurses' population above would be an appropriate group in which to study incident 
coronary disease. This information is usually found either in descriptions of population recruitment, 
definitions of variables, or inclusion/exclusion criteria. 
You may need to look at prior papers on methods in order to make the assessment for this question. 
Those papers are usually in the reference list. 
If fewer than 50% of eligible persons participated in the study, then there is concern that the study 
population does not adequately represent the target population. This increases the risk of bias. 
Question 4. Groups recruited from the same population and uniform eligibility criteria 
Were the inclusion and exclusion criteria developed prior to recruitment or selection of the study 
population? Were the same underlying criteria used for all of the subjects involved? This issue is 
related to the description of the study population, above, and you may find the information for both of 
these questions in the same section of the paper. 
Most cohort studies begin with the selection of the cohort; participants in this cohort are then measured 
or evaluated to determine their exposure status. However, some cohort studies may recruit or select 
exposed participants in a different time or place than unexposed participants, especially retrospective 
cohort studies–which is when data are obtained from the past (retrospectively), but the analysis 
examines exposures prior to outcomes. For example, one research question could be whether diabetic 
men with clinical depression are at higher risk for cardiovascular disease than those without clinical 
depression. So, diabetic men with depression might be selected from a mental health clinic, while 
diabetic men without depression might be selected from an internal medicine or endocrinology clinic. 
This study recruits groups from different clinic populations, so this example would get a "no." 
However, the women nurses described in the question above were selected based on the same 
inclusion/exclusion criteria, so that example would get a "yes." 
Question 5. Sample size justification 
Did the authors present their reasons for selecting or recruiting the number of people included or 
analyzed? Do they note or discuss the statistical power of the study? This question is about whether or 
not the study had enough participants to detect an association if one truly existed. 
A paragraph in the methods section of the article may explain the sample size needed to detect a 
hypothesized difference in outcomes. You may also find a discussion of power in the discussion 
section (such as the study had 85 percent power to detect a 20 percent increase in the rate of an 




effect size are given, instead of sample size calculations. In any of these cases, the answer would be 
"yes." 
However, observational cohort studies often do not report anything about power or sample sizes 
because the analyses are exploratory in nature. In this case, the answer would be "no." This is not a 
"fatal flaw." It just may indicate that attention was not paid to whether the study was sufficiently sized 
to answer a prespecified question–i.e., it may have been an exploratory, hypothesis-generating study. 
Question 6. Exposure assessed prior to outcome measurement 
This question is important because, in order to determine whether an exposure causes an outcome, the 
exposure must come before the outcome. 
For some prospective cohort studies, the investigator enrolls the cohort and then determines the 
exposure status of various members of the cohort (large epidemiological studies like Framingham used 
this approach). However, for other cohort studies, the cohort is selected based on its exposure status, as 
in the example above of depressed diabetic men (the exposure being depression). Other examples 
include a cohort identified by its exposure to fluoridated drinking water and then compared to a cohort 
living in an area without fluoridated water, or a cohort of military personnel exposed to combat in the 
Gulf War compared to a cohort of military personnel not deployed in a combat zone. 
With either of these types of cohort studies, the cohort is followed forward in time (i.e., prospectively) 
to assess the outcomes that occurred in the exposed members compared to nonexposed members of the 
cohort. Therefore, you begin the study in the present by looking at groups that were exposed (or not) to 
some biological or behavioral factor, intervention, etc., and then you follow them forward in time to 
examine outcomes. If a cohort study is conducted properly, the answer to this question should be "yes," 
since the exposure status of members of the cohort was determined at the beginning of the study before 
the outcomes occurred. 
For retrospective cohort studies, the same principal applies. The difference is that, rather than 
identifying a cohort in the present and following them forward in time, the investigators go back in 
time (i.e., retrospectively) and select a cohort based on their exposure status in the past and then follow 
them forward to assess the outcomes that occurred in the exposed and nonexposed cohort members. 
Because in retrospective cohort studies the exposure and outcomes may have already occurred (it 
depends on how long they follow the cohort), it is important to make sure that the exposure preceded 
the outcome. 
Sometimes cross-sectional studies are conducted (or cross-sectional analyses of cohort-study data), 
where the exposures and outcomes are measured during the same timeframe. As a result, cross-
sectional analyses provide weaker evidence than regular cohort studies regarding a potential causal 
relationship between exposures and outcomes. For cross-sectional analyses, the answer to Question 6 
should be "no." 
Question 7. Sufficient timeframe to see an effect 
Did the study allow enough time for a sufficient number of outcomes to occur or be observed, or 
enough time for an exposure to have a biological effect on an outcome? In the examples given above, if 
clinical depression has a biological effect on increasing risk for CVD, such an effect may take years. In 
the other example, if higher dietary sodium increases BP, a short timeframe may be sufficient to assess 





The issue of timeframe is important to enable meaningful analysis of the relationships between 
exposures and outcomes to be conducted. This often requires at least several years, especially when 
looking at health outcomes, but it depends on the research question and outcomes being examined. 
Cross-sectional analyses allow no time to see an effect, since the exposures and outcomes are assessed 
at the same time, so those would get a "no" response. 
Question 8. Different levels of the exposure of interest 
If the exposure can be defined as a range (examples: drug dosage, amount of physical activity, amount 
of sodium consumed), were multiple categories of that exposure assessed? (for example, for drugs: not 
on the medication, on a low dose, medium dose, high dose; for dietary sodium, higher than average 
U.S. consumption, lower than recommended consumption, between the two). Sometimes discrete 
categories of exposure are not used, but instead exposures are measured as continuous variables (for 
example, mg/day of dietary sodium or BP values). 
In any case, studying different levels of exposure (where possible) enables investigators to assess 
trends or dose-response relationships between exposures and outcomes–e.g., the higher the exposure, 
the greater the rate of the health outcome. The presence of trends or dose-response relationships lends 
credibility to the hypothesis of causality between exposure and outcome. 
For some exposures, however, this question may not be applicable (e.g., the exposure may be a 
dichotomous variable like living in a rural setting versus an urban setting, or vaccinated/not vaccinated 
with a one-time vaccine). If there are only two possible exposures (yes/no), then this question should 
be given an "NA," and it should not count negatively towards the quality rating. 
Question 9. Exposure measures and assessment 
Were the exposure measures defined in detail? Were the tools or methods used to measure exposure 
accurate and reliable–for example, have they been validated or are they objective? This issue is 
important as it influences confidence in the reported exposures. When exposures are measured with 
less accuracy or validity, it is harder to see an association between exposure and outcome even if one 
exists. Also as important is whether the exposures were assessed in the same manner within groups and 
between groups; if not, bias may result. 
For example, retrospective self-report of dietary salt intake is not as valid and reliable as prospectively 
using a standardized dietary log plus testing participants' urine for sodium content. Another example is 
measurement of BP, where there may be quite a difference between usual care, where clinicians 
measure BP however it is done in their practice setting (which can vary considerably), and use of 
trained BP assessors using standardized equipment (e.g., the same BP device which has been tested and 
calibrated) and a standardized protocol (e.g., patient is seated for 5 minutes with feet flat on the floor, 
BP is taken twice in each arm, and all four measurements are averaged). In each of these cases, the 
former would get a "no" and the latter a "yes." 
Here is a final example that illustrates the point about why it is important to assess exposures 
consistently across all groups: If people with higher BP (exposed cohort) are seen by their providers 
more frequently than those without elevated BP (nonexposed group), it also increases the chances of 
detecting and documenting changes in health outcomes, including CVD-related events. Therefore, it 
may lead to the conclusion that higher BP leads to more CVD events. This may be true, but it could 
also be due to the fact that the subjects with higher BP were seen more often; thus, more CVD-related 
events were detected and documented simply because they had more encounters with the health care 
system. Thus, it could bias the results and lead to an erroneous conclusion. 




Was the exposure for each person measured more than once during the course of the study period? 
Multiple measurements with the same result increase our confidence that the exposure status was 
correctly classified. Also, multiple measurements enable investigators to look at changes in exposure 
over time, for example, people who ate high dietary sodium throughout the followup period, compared 
to those who started out high then reduced their intake, compared to those who ate low sodium 
throughout. Once again, this may not be applicable in all cases. In many older studies, exposure was 
measured only at baseline. However, multiple exposure measurements do result in a stronger study 
design. 
Question 11. Outcome measures 
Were the outcomes defined in detail? Were the tools or methods for measuring outcomes accurate and 
reliable–for example, have they been validated or are they objective? This issue is important because it 
influences confidence in the validity of study results. Also important is whether the outcomes were 
assessed in the same manner within groups and between groups. 
An example of an outcome measure that is objective, accurate, and reliable is death–the outcome 
measured with more accuracy than any other. But even with a measure as objective as death, there can 
be differences in the accuracy and reliability of how death was assessed by the investigators. Did they 
base it on an autopsy report, death certificate, death registry, or report from a family member? Another 
example is a study of whether dietary fat intake is related to blood cholesterol level (cholesterol level 
being the outcome), and the cholesterol level is measured from fasting blood samples that are all sent to 
the same laboratory. These examples would get a "yes." An example of a "no" would be self-report by 
subjects that they had a heart attack, or self-report of how much they weigh (if body weight is the 
outcome of interest). 
Similar to the example in Question 9, results may be biased if one group (e.g., people with high BP) is 
seen more frequently than another group (people with normal BP) because more frequent encounters 
with the health care system increases the chances of outcomes being detected and documented. 
Question 12. Blinding of outcome assessors 
Blinding means that outcome assessors did not know whether the participant was exposed or 
unexposed. It is also sometimes called "masking." The objective is to look for evidence in the article 
that the person(s) assessing the outcome(s) for the study (for example, examining medical records to 
determine the outcomes that occurred in the exposed and comparison groups) is masked to the 
exposure status of the participant. Sometimes the person measuring the exposure is the same person 
conducting the outcome assessment. In this case, the outcome assessor would most likely not be 
blinded to exposure status because they also took measurements of exposures. If so, make a note of that 
in the comments section. 
As you assess this criterion, think about whether it is likely that the person(s) doing the outcome 
assessment would know (or be able to figure out) the exposure status of the study participants. If the 
answer is no, then blinding is adequate. An example of adequate blinding of the outcome assessors is to 
create a separate committee, whose members were not involved in the care of the patient and had no 
information about the study participants' exposure status. The committee would then be provided with 
copies of participants' medical records, which had been stripped of any potential exposure information 
or personally identifiable information. The committee would then review the records for prespecified 
outcomes according to the study protocol. If blinding was not possible, which is sometimes the case, 
mark "NA" and explain the potential for bias. 




Higher overall followup rates are always better than lower followup rates, even though higher rates are 
expected in shorter studies, whereas lower overall followup rates are often seen in studies of longer 
duration. Usually, an acceptable overall followup rate is considered 80 percent or more of participants 
whose exposures were measured at baseline. However, this is just a general guideline. For example, a 
6-month cohort study examining the relationship between dietary sodium intake and BP level may have 
over 90 percent followup, but a 20-year cohort study examining effects of sodium intake on stroke may 
have only a 65 percent followup rate. 
Question 14. Statistical analyses 
Were key potential confounding variables measured and adjusted for, such as by statistical adjustment 
for baseline differences? Logistic regression or other regression methods are often used to account for 
the influence of variables not of interest. 
This is a key issue in cohort studies, because statistical analyses need to control for potential 
confounders, in contrast to an RCT, where the randomization process controls for potential 
confounders. All key factors that may be associated both with the exposure of interest and the 
outcome–that are not of interest to the research question–should be controlled for in the analyses. 
For example, in a study of the relationship between cardiorespiratory fitness and CVD events (heart 
attacks and strokes), the study should control for age, BP, blood cholesterol, and body weight, because 
all of these factors are associated both with low fitness and with CVD events. Well-done cohort studies 
control for multiple potential confounders. 
Some general guidance for determining the overall quality rating of observational cohort and 
cross-sectional studies 
The questions on the form are designed to help you focus on the key concepts for evaluating the 
internal validity of a study. They are not intended to create a list that you simply tally up to arrive at a 
summary judgment of quality. 
Internal validity for cohort studies is the extent to which the results reported in the study can truly be 
attributed to the exposure being evaluated and not to flaws in the design or conduct of the study–in 
other words, the ability of the study to draw associative conclusions about the effects of the exposures 
being studied on outcomes. Any such flaws can increase the risk of bias. 
Critical appraisal involves considering the risk of potential for selection bias, information bias, 
measurement bias, or confounding (the mixture of exposures that one cannot tease out from each 
other). Examples of confounding include co-interventions, differences at baseline in patient 
characteristics, and other issues throughout the questions above. High risk of bias translates to a rating 
of poor quality. Low risk of bias translates to a rating of good quality. (Thus, the greater the risk of 
bias, the lower the quality rating of the study.) 
In addition, the more attention in the study design to issues that can help determine whether there is a 
causal relationship between the exposure and outcome, the higher quality the study. These include 
exposures occurring prior to outcomes, evaluation of a dose-response gradient, accuracy of 
measurement of both exposure and outcome, sufficient timeframe to see an effect, and appropriate 
control for confounding–all concepts reflected in the tool. 
Generally, when you evaluate a study, you will not see a "fatal flaw," but you will find some risk of 
bias. By focusing on the concepts underlying the questions in the quality assessment tool, you should 
ask yourself about the potential for bias in the study you are critically appraising. For any box where 
you check "no" you should ask, "What is the potential risk of bias resulting from this flaw in study 




study or doubt the ability of the study to accurately assess an association between exposure and 
outcome? 
The best approach is to think about the questions in the tool and how each one tells you something 
about the potential for bias in a study. The more you familiarize yourself with the key concepts, the 
more comfortable you will be with critical appraisal. Examples of studies rated good, fair, and poor are 
useful, but each study must be assessed on its own based on the details that are reported and 






Appendix 6. The quality criteria for critical appraisal of observational studies 
adapted from the CRD handbook 
 
Quality criteria for critical appraisal of observational studies 
1. Are the study participants adequately described? For example look for adequate 
descriptive data on age, sex, baseline health status, and other relevant variables. 
2. If there is a comparison or control group, are they similar to the intervention group, 
in terms of variables that may affect the outcome of the intervention (including 
demographic and other socio-demographic characteristics). This may be achieved by 
matching or other means – it may be taken into account in the statistical analysis – for 
example, by means of ANCOVA or regression techniques. 
3. If the study involves an assessment of an intervention, is the intervention clearly 
described, with details of who exactly received it? 
4. If the study is an etiological study (e.g., does maternal stress cause behaviour 
problems in children?) were the independent and dependent variables adequately 
measured (that is, was the measurement likely to be valid and reliable)? This may 
include valid reliable measures, such as well-validated questionnaires if appropriate. 
5. Are the measures used in the study the most relevant ones for answering the research 
question? 
6. If the study involves following participants up over time, what proportion of people 
who were enrolled in the study at the beginning, dropped out? Have these ‘‘drop-outs’’ 
introduced bias? 
7. Is the study long enough, and large enough to allow changes in the outcome of 
interest to be identified? 
8. If two groups are being compared, are the two groups similar, and were they treated 
similarly within the study? If not, was any attempt made to control for these differences, 
either statistically, or by matching? Was it successful? 
9. Was outcome assessment blind to exposure status? (That is, is it possible that those 
measuring the outcome introduced bias?) 
(Adapted from the CRD handbook) 
Source: Mark Petticrew; Helen Roberts. Systematic reviews in the social science: a practical guild; 
Chapter 5; 136. https://ia801603.us.archive.org/31/items/B-001-002-450/Pettigrew-Roberts-SR-in-the-
Soc-Sc.pdf  
